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Abstract

Research has demonstrated that the atypical protein kinase C-zeta (PKC-ζ) is a component of many
dysregulated pathways in breast and ovarian cancer, including cellular proliferation, survival, and
cell cycle upregulation. Breast and ovarian cancers affect women every day and are second and
fifth leading cause of cancer death. Women who seek treatments are commonly met with invasive
surgeries or chemotherapy. Protein kinase C (PKC) is a family of serine and threonine
phosphorylating kinases that have been shown to modulate and transduce signaling cascades that
play roles in the development and survival of cancers. Atypical PKC (aPKC), have been heavily
suggested to participate in phosphoinositide 3-kinase (PI3K) misregulated cancers (such as breast
and ovarian) and inhibition of these pathway branches have demonstrated decreases in malignant
behaviors. In our studies, we investigated (1) PKC-ζ protein in breast tissue to evaluate its
potential as a biomarker for breast cancer invasion and (2) the effects of the atypical PKC-ζ
inhibitor ζ-Stat on ovarian cell lines (TOV21G and ES-2) to determine the outcomes on
proliferation and cellular invasion. In breast cancer tissues, we showed that an overexpression of
PKC-ζ protein can be indicative of carcinogenesis. We also evaluated the invasive behavior of
MDA-MB-231 breast cancer cells upon the knockdown of PKC-ζ with a Transwell invasion assay
and an immunofluorescent probe for filamentous actin (F-actin) organization. In ovarian cancer,
we utilized clear cell ovarian carcinoma cells (CCOC) because this subtype of ovarian cancer
represents 5% of incidence, presents unique pathological features, has poor prognosis and has a
high reoccurrence rate after treatment. Overall, our results showed that PKC-ζ is linked to
viii

proliferation and invasion in both breast and ovarian cancer. These results illustrate that PKC-ζ
plays a role in invasion pathways through the Ras-related C3 botulinum toxin substrate 1 (Rac1)
and Ras homolog gene family member A (RhoA). Additionally, our results showed that TOV21G
tumor growth in athymic female mice was decreased when treated with the PKC-ζ inhibitor, ζStat. These data suggests that PKC-ζ is a biomarker and a novel target in the carcinogenesis of
breast and CCOC and its inhibition by way of ζ-Stat decreased the rate of proliferation, tumor
growth and expression of invasive protein pathways.

ix

Chapter 1: Protein Kinase C

1.1. Introduction
There are many routes to cancer development and evolution. Healthy functioning intracellular
signaling proteins make cellular homeostasis and regulation possible. However, when these
signaling cascades become irregular, small changes can occur in the cellular environment.
Overtime, these aberrations can accumulate and transform a functioning “normal” cell into a
tumorigenic cell.
In the early 1980s, protein kinase C became a focus of interest in tumorgenesis. Phorbol esters
had long been of interest in cancer development. Phorbol esters were shown to promote
tumorigenesis in mice via prolonged topical treatment to the skin; however the proteins that
relayed the messages from these natural products remained aloof 2. The Protein Kinase C (PKC)
enzymes were first identified by Nishizuka and collaborators; it was five years later that the
proteins were discovered to be activated by phorbol esters which 3. This discovery launched a drug
discovery movement with the PKC family in its scope.

1.2. PKC isoforms, activation mechanisms and domains
PKCs are an enzymatic family of proteins that have been found to be a component in cancer
progression 4. These proteins are phosphorylated on serine and threonine residues and are generally
1

activated by secondary messengers such as diacylglycerol (DAG), calcium (Ca2+) and phorbol
esters

2,4

. PKCs are also activated when they localize to the cellular membrane and interact with

phosphatidylserine (PS). Phorbol esters are an analog of diacylglycerols, which also have similar
structures to phospholipids such as phosphatidylserine (Figure 1.1).

Figure 1.1 Backbones of phorbol esters, DAG and phosphatidylserine.

Activation of these proteins varies based on isoform specific domains. There are three isoform
classifications within the PKC family: conventional PKC-α, PKC-βI and PKC-βII (splice variant)
and PKC-γ; novel PKC-δ, PKC-ε, PKC-η and PKC-θ; and the atypical PKC-ζ and PKC-ι/λ4. DAG,
calcium and PS, activates the conventional PKC isoforms while the novel PKC isoforms are only
2

activated by DAG and PS and are calcium insensitive (Figure 1.2). The atypical PKC are both
DAG and calcium insensitive but can be activated by PS as well as Partitioning Defective 6 (Par6)
complexing 4. The unique regulation of the different classifications of this protein family is
determined on the presence or absence of domains and motifs.

Figure 1.2 PKC enzyme activation and domains. The three subgroups of the PKC family are conventional, novel and
atypical. While all three groups have a regulatory and catalytic domain, there is great variation between the domains
and hinge regions homology. Phospholipids, calcium and DAG are the secondary messengers that activate these
proteins 5,6. The V1-5 represent the variable regions of the proteins. Note: Data for this figure was taken from
references 5 and 6.

The diverse domains of the PKC family of enzymes perform many tasks in regulation, cellular
localization and phosphorylation. The C1 and C2 domains (regulatory) position the PKC on the
inner leaflet of the plasma membrane and are the portion of the protein where DAG and calcium
activate the protein, respectively 4. Phorbol esters create a response by involvement with the twin
conserved zinc fingers C1A and C1B 4. Adenosine triphosphate (ATP) binds to the C3 domain,

3

and the catalytic kinase site has three phosphorylation sites known as the activation loop residue,
turn motif and hydrophobic site 4.
Furthermore, the different regions of PKC proteins are what give it unique characteristics and
behavior. The pseudo-substrate site (ψ-substrate), which is a part of the regulatory domain, mimics
a substrate consensus sequence for PKC except instead of having a serine/threonine to
phosphorylate, it has an alanine (Figure 1.2) 4,6–8. This site binds to the catalytic kinase domain of
the protein, folding the protein in half and causing its deactivation. The V3 region is the hinge at
which the protein folds when inactivated or when the pseudo-substrate is bond to the catalytic
domain 6. The C1 domain is cysteine rich, has two repeats and participates in protein-protein
interaction (possibly with G proteins)4. The C2 domain mediates intermolecular interactions, is a
β sandwich (two sheets of four components) and binds negatively charged phospholipids, such as
PS 4. The C3 and C4 domain are the ATP and substrate binding sites as well as the kinase activity
site 4. The V5 region is highly flexible and contains an important posttranslational phosphorylation
site within the PKC and is needed to make the protein mature 4.

1.3. Atypical PKC as novel targets for cancer therapy
The PKC family members have been found to regulate many malignant pathways and play a
significant role in cancer development. In particular, the atypical isoforms (PKC-ι and PKC-ζ)
have been suggested to participate in oncogenesis at varying levels and tissue specificity 9. In
addition, the aPKCs have been linked to cancer progression in non-small cell lung, epithelial
ovarian, breast, prostate and colon carcinomas 10–16. Interestingly, many PKC isoforms are located
on different chromosomes, apart from PKC-ι and PKC-δ (located on the long arm of chromosome

4

three). This trend holds true as far as the atypical which are located on separate chromosomes
(PKC-ι on 3q26 and PKC-ζ on 1p36) and have been noted to perform non-redundant tasks. A
comparison of sequence identities between the most conserved amino acid domains of PKC
isoforms illustrates the closest homology of PKC-ι and PKC-ζ (77% in the first zinc finger and
84% in the catalytic domain) (Table 1.1) 17.

Table 1.1 Sequence identities match between PKC-ι and PKC isoforms in first zinc finger (C1a) and catalytic domain.
The table represents a homology comparison of the two most conserved domains in the PKC isoforms with PKC-ι.
The genomic location of PKC isoforms was found with the GeneCards Human Gene Database 17,18. Note: Data for
this table was used from references 17 and 18.

Sequence identities match between PKC-ι and PKC isoforms in first zinc finger and catalytic
domain
PKC isoform
First zinc finger
Catalytic domain
Chromosomal
location
ι
100
100
3q26.2
α
40
50
17q24.2
β
40
52
16p12.2
γ
39
48
19q13.42
δ
32
48
3p21.1
θ
34
44
10p15.1
ε
39
53
2p21
η
38
51
14q23.1
ζ
77
84
1p36.33

Although the genes PRKCI and PRKCZ (PKC-ι and PKC-ζ) are not commonly mutated in
cancer, they have been found to be overexpressed. The long arm of the third chromosome has been
found to be a frequent amplicon and driver in epithelial malignant tissue growth 19. Genes that are
found overexpressed on the 3q26 portion of chromosome three are ECT2, SOX2, PRKCI and
PIK3CA 19. In an investigation by Fields et al., the authors found that cancers affected by the copy
number gains of the 3q26 amplicon were most abundant in lung squamous, esophagus, ovarian,
cervix and head and neck squamous cell carcinoma
5

19

. Furthermore, PKC-ι overexpression has

been observed in several cancers including melanoma, neuroblastoma and prostate

11,20,21

. This

overexpression of aPKC is another reason that research has searched for inhibitors specific to PKC.

1.3.1. PKC inhibitors
For the last 20 years, PKC-specific inhibitors has been a goal of academia and industrial
research. Three modes of inhibition have made great strides and include (a) competitive small
molecule inhibitors for the ATP site, (b) activators that mimic phorbol esters that bind to the C1
domain and (c) peptides that disrupt protein-protein interactions 3. The pan-PKC inhibitor
Staurosporine is the most studied ATP binding small molecule and it binds all isozymes (due to
high homology in the ATP site) 3. In addition, a naturally occurring macro lactone called Bryostatin
has shown anti-cancer properties and clinical relevance 3,22. Bryostatin is known to mimic DAG
binding in the C1 domain of PKC isoforms and reduce proliferation 3,22. However, the results from
clinical trials for PKC inhibitors have been mixed and challenging 3. New inhibitor development
for this protein family is essential for the molecular targeting of PKC, cancer treatment and chemo
sensitization.
With an emphasis on aPKC small molecule inhibitors, ICA-1 and ζ-Stat have been studied.
ICA-1 was first published in cancer treatment in 2011 by Pillai et al. These investigators
determined through in-silico molecular docking that ICA-1 was specific to PKC-ι and bound to
the amino acids 469-475 (glutamine, isoleucine, arginine, isoleucine, proline, arginine and serine)
21

. Further studies have shown that ICA-1 decreased the proliferation and invasion of

neuroblastoma, glioblastoma, melanoma, prostate and colorectal cells

10, 20,21,23,24

. Shortly after

ICA-1 emerged, ζ-Stat soon came into view as a PKC-ζ specific inhibitor and showed great

6

potential in disrupting aberrant PKC pathways

10,20

. Furthermore, studies of the combination of

these small molecule inhibitors with FDA approved drugs have begun to surface and show
excellent promise. The combination of 5-fluorouracil (chemotherapeutic drug) and ζ-Stat
significantly reduced the growth and migration of colorectal cells and caused a synergistic effect
for DNA fragmentation

25

. The drugs ICA-1 and ζ-Stat should continue to be developed due to

their continued relevance to cancer treatment.

1.4. With a closer look a PKC-ζ
Although PKC-ι has been greatly studied and is characterized as an oncogene, the roles PKCζ are still under dispute. Research has shown that PKC-ζ behaves as proapoptotic tumor suppressor
as well as an oncogenic driver

4,26

. As mentioned before, PKC-ι is on the common epithelial

amplicon 3q26; however, PKC-ζ is on the short arm of the first chromosome. An investigation by
Ragnarsson et al. showed that in 683 human solids tumors from different locations in the body,
369 (54%) demonstrated a loss of heterozygosity in the distal portion of chromosome 1p 27. These
high percentages of loss of heterozygosity were seen in the 1p36, 1p35-p34, 1p32 and 1p31 regions
27

. A loss in heterozygosity is common in cancer development and means that there is a somatic

loss of a wild-type allele for a tumor suppressor gene

28

. These data indicate that the genomic

location of PRKCZ (1p36.33) may make this gene susceptible to loss of heterozygosity and the
loss of its tumor suppressor function, therefore transforming this protein into an oncogene.
Moreover, PKC-ζ (and PKC-ι) has been shown to be down stream of the phosphoinositide 3kinase (PI3K) signaling pathway. This pathway is one of the most altered pathways in human
cancer and is the focus of many targeted inhibitors

7

29

. PKC-ζ resides in a branch of the PI3K

pathway that controls signaling cascades related to apoptosis, motility and proliferation (Figure
1.3). Previous studies have shown that the inhibition of PKC-ζ activity or PRKCZ gene knockdown
caused significant decreases in cell proliferation, movement and death 10,30,31. In support, research
performed by Islam et al. demonstrated that the treatment of colorectal cells with the PKC-ζ novel
inhibitor ζ-Stat significantly decreased the wound healing and cell viability 10. Research continues
to reiterate the importance of targeting PKC-ζ to shut down these transduction pathways and
decrease a tumor’s overall malignancy.

PI3K

PKC - ι

Invasion

PKC - ζ

Tumor
growth

Survival

Figure 1.3 - Atypical PKC are downstream of PI3K pathway. The atypical PKC are downstream of the PI3K signaling
cascade and can regulate phenotypic responses such as invasion, tumor growth and survival.

1.4.1. PKC-ζ in invasion pathways
Additionally, PKC-ζ has been implicated in migration and invasion specific pathways. PKC-ζ
has been noted to regulate cell invasion through indirect actin reorganization and RhoA family
activation. Rho family GTPases (i.e. Rac1, Cdc42 (Cell division control protein 42 homolog),
RhoA) are activated through the Par6/Par3/aPKC complex. Par6 and Par3 (Partitioning defective
3) are scaffolding proteins that complex with one another due to the presence of their PDZ domain
32

. This complex is further known to interact with the aPKC through the unique PB1 (Phox and
8

Bem1) domain 32. The CRIB (Cdc42/Rac interactive binding) domain (located in proximity of the
Par6 PB1 domain) further interacts with GTP (guanosine triphosphate) bound Rho GTPases such
as Cdc42 and Rac1 32. Analysis by the STRING network database strengthens this argument. This
database simplifies access to protein-protein interactions (either direct or indirect) by collecting
high-throughput experimental data, mining databases and literature and utilizing predictions from
genomic context analysis

33

. According to this database, the assessment of this web of proteins

demonstrated (a) a high potential of association for RHOA (RhoA), RAC1 (Rac1), CDC42
(Cdc42), PRKCI (PKC-ι), PRKCZ (PKC-ζ), PARD6A (Par6) and PARD3 (Par3) and (b) that these
proteins play a role in cellular polarity and junction assembly (Figure 1.4) 33.
Cell polarity is essential in invasion and migration. Some normal functions of cell migration
are wound healing and embryotic development; however abnormal behavior in these biological
processes can cause tumor metastasis

34

. The two types of migration are defined as (a) random

migration where cells migrate in all directions and (b) directed migration where cells migrate in a
given direction

35

. In both instances, the front and rear axis of the cell are polarized by actin

reorganization and polymerization

35

. Cdc42, Rac and RhoA regulate this cytoskeleton

rearrangement and can make actin filament-based structures assemble and disassemble (including
filopodia, invadopodia and lamellipodia)

34,36

. These Rho GTPases are activated by the guanine

exchange factor (GEF) epithelial cell transforming 2 protein (Ect2). This process involves the Ect2
protein exchanging the GDP (guanosine diphosphate) for a GTP in the Rho GTPases. Once
activated, the conformational changes (between inactive and activate states) in the Rho proteins
allows for the binding of the CRIB domain to further signaling molecules, such as p21 activating
kinase (PAK) and Par6 32,37–40.

9

Figure 1.4 String interaction network of cellular polarity complex via Rho GTPase interaction with aPKC/Par/Par3
33
. This is a depiction of an interaction network derived from STRING v11. The inputted protein names were RHOA
(RhoA), RAC1 (Rac1), CDC42 (Cdc42), PRKCI (PKC-ι), PRKCZ (PKC-ζ), PARD6A (Par6) and PARD3 (Par3).
This interaction network had 7 nodes, 21 edges, 6 average node degrees and a PPI enrichment p-value of 2.22 e-15.
This means that the inputted proteins have more predicted interactions among themselves than what would be expected
for a random set of proteins of similar size, drawn from the genome. Such an enrichment indicates that the proteins
are at least partially biologically connected, as a group. Analyses of (a) establishment or maintenance of cell polarity
(red nodes) and (b) cell junction assembly (blue nodes) were also performed with a false discovery rate (FDR) of
2.80e-09 and 1.28e-07, respectively. Note: Data for this figure was taken from reference 34.

Additionally, Ect2 plays different roles in normal and malignant cells. Ect2 has many normal
functions, including cytokinesis, where it is found in the nucleus. However, in transformed
malignant cells, Ect2 is mislocalized and is commonly found in the cytosol where it participates
in migratory pathways (Figure 1.5)

15,41

. The investigators Fields et al. found that Ect2 was an

oncogene in human cancer and participated in the Par6/Par3/aPKC polarity complex

42–44

. The

mislocalization of Ect2 via the Par6/aPKC scaffold allowed for increased Ect2 activation of
cytosolic Rac1 44. In Ect2-deficient non-small cell lung cancer cells (by RNAi), the authors found
that Rac1 activation, anchorage-independent growth and invasion were all inhibited

10

44

. Their

findings suggest that oncogenic Ect2 inhibition via the disruption of the Par6/Par3/aPKC complex
may decrease the aggressive behavior of cancer cells and decrease the chances of later stage
metastases.

RhoA

Ect2
Cdc42

Rac1

Figure 1.5 Ect2 functions and activation of the Rho GTPases Cdc42, RhoA and Rac1. In normal cells the GEF Ect2
plays a role in processes such as cytokinesis; however in transformed malignant cells, Ect2 has been shown to play
roles in migration and invasion. Ect2 exchanges the GDP for a GTP in Rho GTPases such as RhoA, Cdc42 and Rac1.
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Chapter 2: Role of PKC-ζ in breast cancer

Note to the reader: This article has been published: Smalley, T., Islam, S. M. A., Apostolatos, C.,
Apostolatos, A. & Acevedo-Duncan, M. Analysis of PKC-ζ protein levels in normal and malignant
breast tissue subtypes. Oncol. Lett. 17, 1537–1546 (2019). https://doi.org/10.3892/ol.2018.9792
2.1. Introduction
In the current research, cancer statistics show that invasive breast cancer is projected to have
234,190 new cases and deaths, for which 231,840 will be women 45. Approximately 40,290 women
will die from invasive breast cancer in 2018

46

. Although the percentage of mortalities has

decreased over last few years, breast cancer still ranks as the second leading cause of cancer death
in women; treatments usually entail invasive surgeries, including breast-conserving surgeries and
mastectomies 45. From a clinical standpoint, invasive ductal carcinoma is the most common form
of breast cancer, affecting 50-75% of breast cancer diagnoses 46. Breast cancer is a heterogeneous
disease, and research has shown that the top mutated genes in breast carcinomas and carcinomas
in-situ are PIK3CA (Phosphatidylinositol-4,5-Bisphosphate 3-Kinase Catalytic Subunit Alpha),
TP53 (Tumor Protein P53), and CDH1 (E-Cadherin)47. However, this investigation shows a link
between PKC-ζ protein overexpression and breast cancer development, particularly in invasive
behavior. For this reason, breast cancer biomarkers are of interest, as they may help to predict
breast cancer incidents and contribute to better therapeutic regimens.

12

The complete understanding of histological and pathological features of the lobular and ductal
carcinomas are far from full elucidation. In an investigation by Ruibal et al., the authors concluded
that, in the absence of the axillary node, lobular carcinomas had a higher concentration of Breast
cancer estrogen-inducible protein (pS2) than ductal carcinomas 12. Lobular carcinomas were also
shown to have a higher frequency of diploidy, which suggests that lobular carcinomas are less
aggressive and grow slower 12.
An overexpression of PKC-ζ protein promotes carcinogenesis by stimulating cancer cell
proliferation through pathways such as the Nuclear Factor Kappa B (NF-κB), which plays an
essential role in cancer initiation and progression

48

. Previous studies suggest that PKC-ζ is a

regulatory factor for the nuclear translocation of NF-κB that in turn represses E-Cadherin

14,49

.

Although the link between the loss of E-Cadherin and cancer prognosis remains ambiguous, recent
findings showed that E-Cadherin possesses a vital tumor suppressive role

50

. Moreover, some

researchers have paralleled PKC-ζ to the phosphorylation of the Inhibitor of Kappa B Kinase
(IKK) complex, which in turn phosphorylates the Inhibitor of Kappa B (IκB) and triggers IκB
degradation

49,51

. The degradation of IκB releases NF-κB, allowing its translocation from the

cytosol into the nucleus, where it functions as a transcription factor 51. The transcription factor
applies explicitly to targets such as apoptosis regulators and stress response genes. Furthermore,
studies show that NF-κB also plays a role in epithelial to mesenchymal transition, a crucial
carcinogenic event 49.
PKC-ζ has also been linked to metastatic behaviors of cancer cells. In a study by Islam et al.,
the Rac1/Pak1/β-Catenin signaling cascade in colorectal cancer cell lines was evaluated after the
inhibition of PKC-ζ 10. The knockdown of PKC-ζ decreased the nuclear translocation of β-Catenin
which ultimately lead to reduced colorectal cell proliferation and metastasis 10. These data were
13

further supported by another investigation performed by Wu et al., which determined that
inhibition of PKC-ζ in breast cancer cell lines decreased adhesion and actin polymerization

31

.

These studies advocate the theory that PKC-ζ is a critical component of the invasive behaviors of
cancer cells.
Although PKC-ζ has been studied in invasive breast cancers (most commonly ductal), there
have been no examinations of PKC-ζ expression in other types of breast cancer (such as
carcinomas in-situ). An investigation by Lin et al. confirmed that atypical protein kinase C
isoforms were elevated in breast cancer tissues (invasive ductal carcinoma, specifically) when
compared to adjacent healthy breast tissue

52

. Additionally, Schöndorf et al. determined that

antineoplastic agents affected the activation of PKC in invasive ductal carcinoma breast cancer
tumors 53. In our study, the focus was to further investigate the PKC-ζ expression profile in the
four histological subtypes of breast cancer such as lobular carcinoma in-situ (LCIS), invasive
lobular carcinoma (ILC), ductal carcinoma in-situ (DCIS) and invasive ductal carcinoma (IDC).
We also evaluated the difference in the PKC-ζ expression among healthy, invasive and noninvasive tissues. Moreover, the invasive characteristics of MDA-MB-231 breast cancer cells were
examined upon the inhibition of PKC-ζ. We found that PKC-ζ was overexpressed in IDC and ILC
tissue specimens compared to other subtypes. In addition, the inhibition of PKC-ζ decreased the
invasion of MDA-MB-231 breast cancer cells.

Table 2.1 The selection of breast specimens with pathological characteristics. Tissue specimen were selected as
described in material and methods and further sorted by the presence of PKC-ζ protein. *LN=lymph node, ER=
estrogen receptor, PR= progesterone receptor, LCIS= lobular carcinoma in-situ, ILC=invasive lobular carcinoma,
IDC=invasive ductal carcinoma, DCIS=ductal carcinoma in-situ, NA=not available.
LN

Grade/Stage

ER

PR

Histology

14

Race

PKC-ζ
expression

Number
of patient
samples

Table 2.1 (Continued)
NA

NA

NA

NA

Normal

Black

no

9

NA

NA

NA

NA

Normal

NA

no

4

NA

NA

NA

NA

Normal

White

no

15

NA

NA

NA

NA

Normal

White

yes

4

NA

NA

NA

NA

LCIS

Black

no

1

+

II/III

-

-

LCIS

White

no

1

+

II/III

+

+

LCIS

White

yes

1

NA

NA

NA

NA

ILC

Black

no

1

-

II/III

NA

NA

ILC

NA

no

1

+

III/III

+

+

ILC

NA

no

1

NA

NA

NA

NA

ILC

NA

no

1

-

I/III

+

+

ILC

White

no

1

-

NA

NA

NA

ILC

White

no

1

+

II/III

+

+

ILC

White

no

1

NA

NA

NA

NA

ILC

White

no

1

+

II/III

+

+

ILC

Black

yes

1

+

III/III

+

+

ILC

NA

yes

1

NA

NA

NA

NA

ILC

NA

yes

1

-

NA

+

+

ILC

White

yes

1

NA

I/III

+

-

ILC

White

yes

1

-

III/III

-

+

IDC

Black

no

1

+

NA

-

+

IDC

Black

no

1

NA

NA

NA

NA

IDC

NA

no

1

-

I/III

+

+

IDC

White

no

1

NA

III/III

NA

NA

IDC

White

no

1

NA

NA

+

-

IDC

White

no

1

NA

NA

+

+

IDC

Black

yes

1

-

II/III

NA

NA

IDC

NA

yes

1

+

III/III

NA

NA

IDC

NA

yes

1

+

III/III

NA

NA

IDC

NA

yes

1

NA

NA

+

-

IDC

NA

yes

1

NA

NA

NA

NA

IDC

NA

yes

2

-

III/III

-

-

IDC

White

yes

2

+

II/I

+

+

IDC

White

yes

1

+

NA

-

-

IDC

White

yes

2

+

NA

-

NA

IDC

White

yes

1

+

NA

+

+

IDC

White

yes

1

+

NA

NA

NA

IDC

White

yes

2

NA

I/III

NA

NA

IDC

White

yes

1

NA

NA

-

-

IDC

White

yes

1

NA

NA

+

-

IDC

White

yes

2

NA

NA

NA

NA

IDC

White

yes

3

NA

NA

NA

NA

DCIS

Black

no

1

NA

NA

NA

NA

DCIS

NA

no

4

-

NA

NA

NA

DCIS

Black

yes

1
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2.2. Results
2.2.1. PKC-ζ is overexpressed in malignant breast tissues
PKC-ζ protein expression was measured in breast samples with no tumor complication and
malignant breast tissue samples by Western Blot analysis. Tissue specimen were selected as
described in material and methods and further sorted by the presence of PKC-ζ protein (Table
2.1). Our investigation showed a correlation between the overexpression of PKC-ζ and malignant
breast cancer tissue (Figure 2.1A, 2.1B; Table 2.3A). It was challenging to obtain DCIS (N=6)
and LCIS (N=3) since these tissue types have lower occurrence rates; hence the results reflect a
comparison of the two main subtypes: IDC, N=29, (50-75% diagnoses) and ILC, N=13 (10-15%
diagnoses). The Westerns represent the majority of samples. Normal tissue only had 3 of 32
samples with expression of PKC-ζ and DCIS only had 1 of 6 samples with PKC-ζ present (Table
2.2).

Table 2.2 The status of PKC-ζ in malignant and healthy breast tissue. Healthy breast tissue was obtained from breast
reductions or the area adjacent to a patient’s malignant tumors. Malignant tumors were either LCIS, ILC, DCIS, or
IDC. The expression of PKC-ζ was evaluated as not present (ratio 0), weakly present (ratio < 0.01) and positively
present (ratio > 0.01).

Tissue Type
Normal tissue
Lobular carcinoma insitu
Invasive lobular
carcinoma
Ductal carcinoma in-situ
Invasive ductal
carcinoma

Not present
29
2

Weakly present
1
1

Positively present
2
0

8

4

1

5
6

0
5

1
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Among the IDC subtypes of malignant breast tissue, over 74% of tissue samples overexpressed
PKC-ζ protein. Less than 5% of healthy breast tissue samples exhibited PKC-ζ protein expression.
16

Although a paired Student's t-test (p < 0.05) and one-way ANOVA (p < 0.01) showed no
significant correlation between the overexpression of PKC-ζ protein in malignant tissue (all four
subtypes) and healthy tissue, it did demonstrate a significant correlation between healthy breast
tissue and IDC (Tukey HSD p-value 0.0056404, p < 0.01; Scheffé p-value 0.0121289, p < 0.05;
Bonferroni and Holm p-value 0.0063104, p < 0.01) (Figure 2.1B). According to the significance
of the contingency table (Table 2.3A), there is an established association between the protein
expression of PKC-ζ and sample type (p < 0.00001). However, the PKC-ζ expression could not be
statistically linked to the presence of ER (estrogen receptor) and nuclear grade (Table 2.3B, 2.3C).
These data suggest that it is unlikely that healthy breast tissue samples overexpress PKC-ζ protein.
Instead, PKC-ζ is overexpressed in malignant breast tissue samples.

Table 2.3 Chi-square statistical analysis results of normal and malignant breast tissue. The Chi-square analysis
compared the absence or presence of PKC-ζ expression (by Western Blot) in different breast tissue specimens.
Comparisons of breast (A) subtype (normal, LCIS, ILC, DCIS, and IDC, N=83), (B) estrogen receptor expression
(N=30) and (C) Scarff-Bloom-Richardson grading (N=22) were evaluated. The ** represents a statistical significance
at p value < 0.00001. LCIS=lobular carcinoma in-situ, ILC=invasive lobular carcinoma, DCIS=ductal carcinoma insitu, IDC=invasive ductal carcinoma, ER=estrogen receptor, NG1-3=nuclear grade 1-3.

A

Normal

LCIS

ILC

DCIS

IDC

Row Totals

PKC-ζ present

3

1

5

1

23

33

PKC-ζ absent

29

2

8

5

6

50

Column Totals

32

3

13

6

29

83 (Grand Total)

**The chi-square statistic is 32.6715. The p-value is < 0.00001. LCIS=lobular carcinoma in-situ,
ILC=invasive lobular carcinoma, DCIS=ductal carcinoma in-situ, IDC=invasive ductal carcinoma

B

ER+

ER-

Row Totals

PKC-ζ present

10

6

16

PKC-ζ absent

6

3

9

Column Totals

16

9

25 (Grand Total)
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The chi-square statistic is 0.0434. The p-value is .834969. The result is not significant at p < .10. ER=estrogen
receptor

C

NG1

NG2

NG3

Row Totals

PKC-ζ present

4

4

5

13

PKC-ζ absent

3

2

4

9

Column Totals

7

6

9

22 (Grand Total)

The chi-square statistic is 0.2. The p-value is .90485. The result is not significant at p < .10. NG1-3=nuclear
grade 1-3

2.2.2

PKC-ζ protein levels are higher in invading breast cancer subtypes

To compare the expression of PKC-ζ in non-invading tissues and invading tissues, Western
Blot and immunohistochemistry were performed. Western Blot data showed that PKC-ζ protein
expression was higher in IDC when compared to the ILC, LCIS and the DCIS (Figure 2.1A, 2.1B).
According to immunohistochemistry findings, breast specimens were scored for the expression of
PKC-ζ by the pathologist (Figure 2.1C). Normal tissue had no to moderate expression (score: 0,2),
LCIS had abundant expression (score: 3,3), ILC had moderate to strong expression (score: 2,3+),
DCIS had moderate to abundant expression (score: 2,3), and IDC had abundant to strong
expression (score: 3,3+). The most robust expression was found to be in ILC and IDC represented
by the 3+ score. However, ILC was found to have moderate to strong expression, whereas IDC
was found to have abundant to strong expression. These findings suggest that PKC-ζ is found
higher in invading tissues when compared to non-invading tissues and more so in IDC when
compared to ILC. These data suggest that the stage between in-situ and invading malignancy can
be correlated to an increased PKC-ζ protein expression.
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Figure 2.1 Western Blot and immunohistochemistry analysis of PKC-ζ expression in normal and malignant tissues.
Malignant tissues were evaluated for the expression of PKC-ζ. (A) We ran 20-30 µg of tissue lysate and probed with
a PKC-ζ antibody. (B) The ratios of PKC-ζ to β-actin in healthy tissue and the four subtypes of malignant breast tissue
were derived using the densitometry. The white bar (healthy) represents the control and the error bars represent the
standard error. The standard deviation, a Student’s t-test (p <0.05) and a one-way ANOVA was used to evaluate the
Western Blot data as well with the post-hoc Tukey’s HSD test (p < 0.01), Scheffé multiple comparison (p < 0.05),
Bonferroni (p < 0.01) and Holm (p < 0.01). Statistical tests showed no meaningful relationship between the healthy
and LCIS, or the ILC and DCIS. The * represents a statistically relevant relationship between normal and IDC breast
tissue. (C) FFPE samples were probed with PKC-ζ and stained for immunohistochemistry. The scoring was based on
the abundance or lack thereof PKC-ζ expression: Score 0 no expression; Score 1 weak expression; Score 2 moderate
expression; Score 3 abundant expression; Score 3 plus (+) strong expression. Image original magnification: 20X.
LCIS= lobular carcinoma in-situ, ILC=invasive lobular carcinoma, IDC=invasive ductal carcinoma, DCIS=ductal
carcinoma in-situ.

2.2.3

PKC-ζ and E-Cadherin levels in tissue specimens

Since the decreased expression of E-Cadherin is indicative of a more aggressive phenotype,
the relationship between PKC-ζ and E-Cadherin protein levels was studied. Western Blot analysis
was used in the context of probing for PKC-ζ and E-Cadherin in IDC breast tissues (Figure 2.2A).
We randomly selected 8 samples out of the 29 IDC tissue specimen to illustrate the data. We could
not establish a significant relationship between PKC-ζ expression and E-Cadherin expression in
19

IDC samples. Our linear regression test (Figure 2.2B) showed no significance (p < 0.05) between
the expressions of PKC-ζ and E-Cadherin protein levels in 20 randomly selected IDC breast tissue
samples. The N value was too low to take into consideration for LCIS, ILC and DCIS. Normal
breast tissues were not taken into consideration since the PKC-ζ expression was only found in 3
samples out of 32. However, our investigation established the relationship between E-Cadherin
protein expression and nuclear grade diagnosis (Figure 2.2C). The Scarff-Bloom-Richardson
scale data was derived from the pathology reports (summarized in Table 2.1). The results show
that E-Cadherin protein expression had an inverse relationship to nuclear grade diagnosis. Even
though the PRKCZ gene is not one of the top mutated genes in breast cancer (carcinomas and
carcinomas in-situ), CDH1 is on the top of the list (Table 2.4) 47.

Figure 2.2 The non-linear relationship between E-Cadherin expression and PKC-ζ expression and the E-Cadherin
ratio measured by tumor nuclear grade in IDC. We investigated the expression of PKC-ζ in comparison to E-Cadherin
expression in IDC diagnosed breast tissues by (A) Western Blot. The Western Blot represents 8 samples of IDC. (B)
We normalized densities of PKC-ζ and E-Cadherin protein expression based on β-actin levels and plotted them on a
scattered plot graph to test for a linear relationship (N=20). (C) The E-Cadherin ratios were further compared to
nuclear grade diagnosis listed on the pathology report, according to the Scarff-Bloom-Richardson scale.
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CDH1

GATA3

Mediator
complex subunit
12
E-cadherin
(Caderin 1)

GATA binding
protein 3

2.2.4

Phosphorylates
certain
signaling
molecules

3q26.3

27

98.97

Substitution
missense

Tumor
suppressor,
regulates cell
cycle
Initiation
of
transcription

17p13.1

24

50.30,
25.20

Substitution
missense,
other

Xq13

20

71.04

Substitution
missense

Cell adhesion

16q22.1

11

28.07,
18.42,
17.54

Transcription
factor

10p15

10

48.58,
16.60

Deletion
frameshift,
substitution
nonsense,
substitution
missense
Insertion
frameshift,
deletion
frameshift

Mutation
Type

Highest
Percent
Mutation (%)

MED12

Percent
Mutation
of
Samples Tested
(%)

TP53

phosphatidylinosi
tal-4,5bisphosphate 3kinase catalytic
subunit alpha
p53

Chromosome
Location

PIK3CA

Protein
Function

Gene

Protein
Product

Table 2.4 Top mutated genes in all breast cancer types. This table was created after a review of the Catalogue of
Somatic Mutations in Cancer database.

PRKCZ gene silencing decreases the invasion of breast cells

To investigate the effects of PKC-ζ inhibition on the invasive behavior of breast cancer
cells, a Transwell invasion assay and immunostaining of F-actin were performed. When compared
to the control, PKC-ζ knockdown decreased the invasion of breast cancer cells by 60% and was
significant (Student’s t-test p < 0.05, one-way ANOVA Tukey HSD p-value 0.0029646, p < 0.01;
Scheffé p-value 0.0049622, p < 0.01; Bonferroni p-value 0.0040067, p < 0.01 and Holm p-value
0.0040067, p < 0.01) (Figure 2.3A, 2.3B). In addition, the levels of two important components of
metastatic pathways, Rac1 and RhoA, were also decreased dramatically (Figure 2.3C). Moreover,
21

MDA-MB-231 breast cancer cells were fixed and stained with phalloidin probe to visualize the
impacts of PRKCZ gene silencing on F-actin organization. The silencing of PRKCZ caused the
reorganization of F-actin around cell cytoskeleton (Figure 2.4). Taken together, these data advance
the theory that PKC-ζ modulates the invasive behavior of breast cancer cells by the regulation of
invasion through the Rac1/RhoA pathway and cytoskeleton filaments.

Figure 2.3 PKC-ζ knockdown retards invasion of MDA-MB-231 breast cancer cells. MDA-MB-231 breast cancer
cells were placed in the upper chamber of Transwell plate coated with 0.5x BME and serum containing media was
placed in the lower chamber as a chemoattractant. Following transfection with siPRKCZ and scrambled RNA, cells
that invaded through the BME and migrated into the lower chamber were stained with crystal violet and (A) observed
under a microscope at 10X magnification (the scale bar represents 1mm). Untreated cells and cells treated with the
transfection reagent (Si-Tran) were also used to establish the effect on invasion. (B) The cells were counted for each
treatment image (N=3), averaged and analyzed with the standard deviation, a Student’s t-test (p <0.05) and a one-way
ANOVA was also used to evaluate the data with the post-hoc Tukey’s HSD test (p < 0.01), Scheffé multiple
comparison (p < 0.01), Bonferroni (p < 0.01) and Holm (p < 0.01). All statistical tests were used to determine the
statistical significance of the invasion data. (C) The cells were further investigated by Western Blot to analyze the
Rac1/RhoA pathway. This data was quantified and averaged for the graph with standard error of the mean represented.
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Figure 2.4 Organization of F-actin upon the knockdown of PKC-ζ. MDA-MB-231 breast cancer cells were treated
with SiTran, scrambled RNA and siPRKCZ for 24 hours. The cells that received no treatment were used as the control.
These cells were then stained with 1X Phalloidin-iFluor 594 and counterstained with DAPI (4′,6-diamidino-2phenylindole). The scale bar represents 100 µm. Original magnification: 20X.
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Chapter 3: ζ-Stat as a novel inhibitor in ovarian cancer

Note to the reader: This paper has been accepted for publication in Frontiers in Oncology:
Women’s Cancer: DOI: 10.3389/fonc.2020.00209
3.1. Introduction
In 2019, it is estimated that approximately 1.7 million new incidences of cancer will be
diagnosed and 600,000 cancer deaths will occur 54. Cancer has become the leading cause of death
in 21 states, despite decreases in cancer death rates since 1991 45. Specifically, ovarian cancer is
estimated to reach 22,530 diagnoses and cause 13,980 cancer deaths per year 54. This constitutes
5% of cancer deaths among women and is responsible for being the most lethal gynecological
cancer diagnosis 55.
The most common ovarian cancer diagnosis is epithelial ovarian carcinomas (EOC), which
constitutes 85-90% of diagnosis

55

. Of this percent, clear cell ovarian carcinoma (CCOC)

represents 5% of incidence and presents unique pathological features and a chemo resistant
phenotype 56,57. CCOC is the third most common subtype of ovarian cancer, has a higher risk of
reoccurrence, and lower survival rate 56. Furthermore, CCOC is characterized as a non-serous (NS)
ovarian cancer and has been found to be more invasive than high grade serous ovarian carcinoma
(HGSOC). It has been found that patients with NS tumors have poor prognosis 58. Consequently,
CCOC is proposed to be associated with endometriosis and it has been suggested that the precancerous lesions from endometriosis can lead to CCOC (relative risk = 12.4)
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59

. Endometrial

cancer and CCOC have been shown to have an overexpression of Protein kinase C (PKC) isoforms
which play important roles in these cancers development and resistance 60.
PKC is an enzymatic family of proteins that have been found to be a component in cancer
progression 2. These proteins phosphorylate the serine and threonine residues of substrates and are
generally activated by compounds such as diacylglycerol (DAG), calcium (Ca2+) and phorbol
esters 2. There are three classifications within the PKC family which include the conventional
PKC-α, βI, βII (splice variant), γ, the novel PKC-δ, ε, η, θ, and the atypical PKC-ζ, ι/λ 2.
The atypical PKC isoforms, PKC-ι and PKC-ζ, have been suggested to participate in the
increased proliferation of ovarian cancer 61. PKC-ι has also been identified as a highly amplified
gene in CCOC

56

and is noted for its role in apical-basal polarity loss

61

. In addition, due to

mutations in the PIK3CA gene and inactivation of Phosphatase and Tensin Homolog (PTEN), the
Phosphoinositide 3-Kinase (PI3K)/ Serine Threonine Kinase 1 (AKT)/ Mechanistic Target Of
Rapamycin Kinase (mTOR) pathway has also been upregulated in CCOC 57,62–64. The upregulation
of this pathway increases the expression of downstream survival targets (e.g. PKC-ζ). PKC-ζ has
been shown to be involved in tumorigenesis, tissue invasion, and cancer progression through the
modulation of cell migration machinery, such as Ras Homolog Family Member A (RhoA), Rac
Family Small GTPase 1 (Rac1), and Epithelial Cell Transforming 2 (Ect2) 10, 51,65.
The ECT2 gene is highly amplified in CCOC and may increase migratory behavior 56. Ect2 is
a Rho GTPase specific guanine nucleotide exchange factor (GEF) which activates this family of
proteins by the addition of a phosphate group to Guanosine diphosphate (GDP)
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.

The

overexpression of Ect2 protein promotes increased activation of the Rho GTPases, which in turn
can facilitates invasion through cytoskeleton reorganization 66.
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Previous studies have indicated that novel aPKC inhibitors ICA-1S and ζ-Stat (Figure 3.1)
decreased the migratory behaviors of colorectal cancer cells and were selective for PKC-ι/λ and
PKC-ζ, respectively

10,20

. These small molecule inhibitors were also shown to decrease cell

viability in colorectal cancer and melanoma 10,20.

Figure 3.1 Atypical PKC inhibitors. The molecular structures and molecular weights of ICA-1S and ζ-Stat. ICA-1S
was synthesized by United Chemistry Resources and ζ-Stat was distributed by the NCI.

Furthermore, computational molecular docking was performed on PKC-ι and a homology
model of PKC-ζ (since there is no crystal structure available) with ICA-1S and ζ-Stat 20. In this
study, the authors suggested that ICA-1S bound to a potential allosteric pocket 20. However, a more
in-depth analysis of ζ-Stat is needed for subsequent studies. The further development of
computational modeling is pivotal for drug discovery optimization and helps push these small
molecule inhibitors towards a clinical setting. Computational studies can generate mechanistic
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understandings of the activity these compounds present, can allow for inhibitor improvement, and
can institute further signaling investigations.
It has been suggested that the distal downstream signal cascade of PI3K/aPKC pathway should
be targeted due to the genotypic and phenotypic reliance of this pathway in CCOC for survival
and invasion. The aims of this study were to further determine the binding mechanisms of ζ-Stat,
expand on the tissue range of these compounds by investigating the effects in CCOC cell lines,
investigate the therapeutic potential of ζ-Stat in CCOC, and to illustrate the disruption of invasion
via the PKC-ζ signaling cascade.

3.2. Results
3.2.1. PIK3CA and ARID1A are in the top mutated genes in all ovarian tissue types and
in CCOC
To understand the genetic landscape of ovarian cancer, we utilized the Catalogue of Somatic
Mutations in Cancer bioinformatics database (COSMIC) 67. The results demonstrated that the top
mutations in ovarian cancer overall are TP53 (p53), FOXL2 (Forkhead box protein L2), KRAS
(Kirsten Ras oncogene homolog), PIK3CA (Phosphatidylinositol 4,5-bispohsphate 3-kinase
catalytic subunit alpha), ARID1A (AT-rich interaction domain 1A) and BRAF (B-Raf protooncogene) (Table 3.1). The search was then refocused to only contain CCOC samples and the top
two mutated genes found were PIK3CA (33%) and ARID1A (50%) (Table 3.2). These results
suggest that one of the most common gene mutations in ovarian cancer and CCOC is PIK3CA,
which is approximately 10% of mutated samples in all the ovarian tissue in the database. Due to
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this, the downstream survival targets PKC-ζ and PKC-ι are likely to be overexpressed, amending
the need for their explicit targeting.

Table 3.1 Six most common gene mutations in all ovarian cancers. The table below describes the six most common
gene mutations in all ovarian cancers according to the Catalogue of Somatic Mutations in Cancer database (COSMIC).
The gene name, protein product, general function, chromosomal location, percent of all samples with mutation, highest
type of mutation and most common mutation type are listed.

Gene

Somatic mutations in all ovarian tissue types
Percent
Mutation
Chromosomal of
Highest
Protein
Location
Samples Percent
Protein Product
Function
(human)
Tested
Mutation

TP53

p53

Tumor suppressor,
regulates cell cycle

17p13.1

46

3q23

20

12p12.1

12

3q26.3

10

1p35.3

9

Substitution
missense
Substitution
missense,
deletion
frame shift,
40, 38.26, insertion
23.48
frame shift

7

Substitution
missense

Transcription

FOXL2 Forkhead box protein L2 factor
KRAS
PIK3CA

Kirsten Ras oncogene
homolog, (KRAS protooncogene, GTPase)
Phosphatidylinosital-4,5bisphosphate 3-kinase
catalytic subunit alpha

AT-rich interaction

ARID1A domain 1A

BRAF

B-Raf proto-oncogene,
serine/threonine kinase

Regulation of cell
division
Phosphorylates
certain signaling
molecules

Regulate
transcription by
altering chromatin
structure
This protein plays
a role in regulating
the MAP
kinase/ERKs
signaling pathway,
which affects cell
division,
differentiation, and
secretion.
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Mutation
Type
Substitution
missense,
55.89,20.23 other
Substitution
100
missense

7q34

100

Substitution
missense

96.88

97.63

In addition, the PIK3CA mutation was used to select two cell lines that would be representative
of this mutation in CCOC. Two commonly utilized cell lines, TOV21G and ES-2 were selected
based on their genetic profile. While both cell lines possess a PIK3CA mutation, TOV21G has an
ARID1A mutation and ES-2 has a TP53 mutation (Table 3.2).

Table 3.2 Somatic mutations in CCOC and CCOC cell lines. The table below describes the five most common gene
mutations in CCOC according to the Catalogue of Somatic Mutations in Cancer database (COSMIC). The gene name
and percent of samples with mutation are listed. The gene mutations for TOV21G CCOC cells and ES-2 CCOC cells
are listed with specific mutation type.

Somatic mutations in CCOC
Percent Mutation of Samples
Tested

Gene

Somatic mutations in cell lines
TOV21G

ES-2

Y551fs*72,Q758fs*75

ARID1A

50

ARID1A

PIK3CA

33

PIK3CA

S241F

TP53

H1047Y

PIK3CA

G13C

TERT

17

KRAS

TP53
KRAS

11
8

PTEN

K267fs*9, G143fs*4

3.2.2. Select inhibitor effects on PKC-ζ and PKC-ι protein expression
To determine which inhibitors affect PKC-ζ and PKC-ι protein expression in CCOC, Western
Blots were employed with ICA-1S and ζ-Stat (Figure 3.1) as potential inhibitors. Initially, the
expression of these aPKCs were investigated in rapidly growing cells (50%) and cell cycle arrested
(serum free, SF) (Figure 3.2A). The density of each band was quantified using analytical software.
The results showed that ICA-1S did not affect PKC-ζ or PKC-ι protein expression (Figure 3.2B);
however, ζ-Stat substantially decreased the expression of PKC-ζ in TOV21G cells (p value
0.00225, F = 9.5709, t = -4.413) and ES-2 cells (not significant) but not PKC-ι protein expression
30

(Figure 3.2C). These results suggest that ζ-Stat is selective to PKC-ζ decreased expression and
could be used to interrupt the PKC-ζ pathways.

Figure 3.2 PKC-ζ and PKC-ι protein expression in rapidly growing and serum starved cells and the effects of ICA1S and ζ-Stat on PKC-ζ and PKC-ι protein expression in SHT290, TOV21G and ES-2 CCOC cell lines. (A) SHT290,
TOV21G and ES-2 cell lines were harvested at 50% and 48 hrs after serum starvation (SF) (N=3). The membranes
were probed with anti-PKC-ζ and PKC-ι to investigate protein expression. (B) TOV21G and ES-2 cell lines were
treated with 3μM ζ-Stat for 24, 48 and 72 hrs. An untreated control and vehicle control (DMSO) are also illustrated.
The immunoblots were probed with PKC-ζ, PKC-ι and β-actin (loading control) (N=3). (C) The raw data’s
densitometry was quantified using ImageJ software and analyzed with a one-way ANOVA. Standard deviation is
represented. (** p < 0.01).

3.2.3. In-silico results and model validation
3.2.3.1.

Model viability
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RMSD and Rg plots of PKC-ι (Figure S3.1) displayed asymptotic behavior beyond 7 ns.
RMSD appeared to equilibrate near 2.3 Å, similar to the reported crystallographic resolution of 2
Å 68. Any additional fluctuation is likely from the disordered tail regions and missing residues 446
– 454 as evidenced from the PKC-ι RMSF plot (Figure S3.2). From these analyses, the MD model
is considered viable due to the ability of the model to accurately maintain the lowest energy
structure under significant perturbation.
To date, no crystallographic structure exists of PKC-ζ. As such, a homology model was
attempted using the Schrödinger program Prime

69–71

with the human PKC-ζ sequence (UniProt

Q05513) and the crystallized PKC-ι structures as templates. PKC-ι was chosen as the primary
template due to its highest sequence identity (49.0%) and homology (53.8%) given from a BLAST
search 72 coupled with highest overall structural resolution. A pre-generated SWISS-MODEL 73–
75

homology model was used as a control for structural reference. The Prime model (Figure 3.3C)

was identical to the SWISS-MODEL variant, so only the Prime model was used for further
analysis. RMSD and Rg plots of the PKC-ζ homology model (Figure S3.3) do show asymptotic
behavior after 1.2 ns, however the RMSD equilibration is averaged to 4.4 Å and is clearly outside
any acceptable resolution. The Rg plot also shows a significant expansion indicative of unfolding
with internal water infiltration. RMSF plots (Figure S3.4) also show substantial backbone
movement beyond 2 Å at regions of PKC-ζ residues differing from PKC-ι with notable disruption
of predicted secondary structure. These factors conclude that the homology model does not
represent a physical low energy structure and therefore cannot be used for further modeling.
Despite this, the ATP binding region is largely stable with RMSF well within reasonable values
(Figure 3.3D). This allows inclusion of the PKC-ζ homology model ATP binding site with
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docking studies to compare binding modes between PKC-ι and PKC-ζ ATP binding sites (Figure
3.3C – yellow region).

Figure 3.3 Computational modeling results. Binding site characterization for PKC-ι ATP site with co-crystallized
ATP shown for reference (A) and the PKC-ι potential allosteric site with ζ-Stat docking result shown for reference
(B). SiteMap analysis for each site is also shown (A and B). Yellow volume denotes hydrophobic regions, red volumes
demarcate hydrogen bond donor sites, and blue volumes define hydrogen bond acceptor sites. The final homology
model structure of PKC-ζ (C) generated is displayed with cartoon ribbons and colored by sequence identity to the
PKC-ι reference structure. Blue are identical residues between both structures with cyan highlighting dissimilar amino
acids. Red indicates sequence spans with no structural template. The ATP binding region is also delineated by a yellow
domain and a magenta domain localizes the suspected allosteric site, both defined by SiteMap. Post-MD RMSD
analysis (D) is illustrated with cartoon ribbons colored by RMSD per residue over the length of the simulation.
Continuous color shift is used to show residue displacement from original structure with blue representing a minimum
of 0 Å RMSD, white representing mid values of 4 Å RMSD, and red representing a maximum of 8 Å RMSD.
Consensus docking scores (E-G) are measured in kcal/mol and represent estimated free energies of binding (ΔGo).
Green highlighting features the best scoring molecule for a particular site and yellow highlight focuses the averaged
consensus scoring for each compound. Theoretical KD values are calculated from free energies of binding (ΔGo).
VTS results are also listed (H).
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The Schrödinger program SiteMap was used for optimizing placement of grids used in the
docking studies and to search for any other potential binding sites. A possible allosteric site for
PKC-ι was identified by SiteMap near residues 397 – 400 in the activation segment of the PKC-ι
c-lobe consisting of a pocket made by α-helices E and F and the interhelical loop between α-helices
H and I (Figure 3.3C – magenta region). SiteMap also scores regions based on potential hydrogen
bonding, hydrophobicity, and pocket volume. Scores of 0.8 or greater are considered the cutoff for
distinguishing between drug-binding and non-drug-binding sites. The PKC-ι ATP site was scored
at 1.004 and the potential allosteric site was scored at 0.779. The potential allosteric site score is
notably within SiteMap calibration error and was still included in docking studies due to proximity
of the pocket with the PKC-ι activation segment and for the possibility of induced fit effects
opening the site.

3.2.3.2.

Docking results

Minimal direct binding data exists for PKC-ι and PKC-ζ so a consensus docking approach was
utilized to gauge the optimal docking algorithm for the ATP and potential allosteric site. The
approach detailed utilizes five different computational methods of discerning theoretical binding
affinities: two unique scoring functions (SP and XP) for ridged docking methods, IFD to account
for potential induced fit effects, QPLD can resolve polarization effects through QM/MM
techniques, and MM/GBSA is superior in clarifying penalties for solvent interactions. Employing
these functions when little empirical evidence exists to correlate results helps identify weaknesses
of each technique for a particular model. Error can also be statistically minimized, yielding a more
accurate summary of ligand binding dispositions and affinities.
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Staurosporine was used as a docking control for the ATP site since binding data exists for both
PKC-ι (261 nM Ki 76, values converted from IC50s) and PKC-ζ (131 nM Ki 77, values converted
from IC50s). ATP is not used as a docking control due to poor model forcefields and lack of direct
binding data.
Docking results are summarized in Figure 3.3E, F, and G. Docking scores for staurosporine
controls are well within reasonable agreement with literature values. Docking scores and poses for
each molecule are nearly identical for the ATP site of PKC-ι and PKC-ζ and both prefer
staurosporine by a significant margin (Figure 3.3E and F, green highlight). XP scoring
consistently yielded scores in closest agreement to literature values and highest Pearson correlation
to overall averages. IFD and QPLD have poorer correlation and control accuracy, suggesting a less
pronounced influence of charge factors and induced fit effects since including polarization and site
flexibility does not increase docking accuracy. MM/GBSA scores exhibit similarly reduced
correlation and high variance, entailing that solvent effects are also not likely a major factor for
binding; this is understandable given the pocket depth. These analyses signify that the hydrophobic
centers of the site (Figure 3.3A) are the dominant factors in ligand binding with the ATP site for
both models. As opposed to the pan-kinase inhibitor, staurosporine, ICA-1S and ζ-Stat display
negligible binding with the ATP site.
The potential allosteric site was also studied (Figure 3.3C&G), but only for PKC-ι since the
corresponding PKC-ζ allosteric site model could not be validated. As such, no conclusions should
be drawn concerning possible interactions of these compounds with any potential allosteric sites
on PKC-ζ (only the ATP site achieved an apparent suitable stability for docking studies). Of the
three molecules, the potential allosteric site appears to prefer only ICA-1S with a theoretical KD
of 1.4 μM. A recent study by Ratnayake et al.
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measured myelin basic protein (MBP)

phosphorylation by PKC-ι and PKC-ζ in the presence of ICA-1S, ICA-1T (the phosphorylated
version of ICA-1S), and ζ-Stat. Docking figures match expected activity of PKC-ι for ζ-Stat having
negligible inhibition. ICA-1S activity as a PKC-ι inhibitor gives some support to the existence of
the potential allosteric site, since modeling suggests that ICA-1S does not interact significantly
with the ATP site, but does display binding at concentrations similar to experimental values for
inducing inhibition. Unfortunately, the data for PKC-ζ is less clear. All the modeling can show is
if the two compounds in question can effectively bind to the ATP site of PKC-ζ. This may
indirectly imply an allosteric site exists for PKC-ζ if inhibition is experimentally observed and the
compound in question does not appear to have favorable docking to the ATP site. For ICA-1S,
there is negligible affinity for the ATP site and experiment reflects a lack of inhibition. Modeling
also suggests an allosteric mechanism may be present for ζ-Stat as binding is also negligible for
the ATP site. Experimental inhibition should be observed for any compounds that compete for the
ATP site since there is no significant difference between the ATP sites of PKC-ι and PKC-ζ.

3.2.3.3.

Virtual target screening results

VTS uses a large curated protein structure library to which molecules of interest are docked.
Statistical calibrations and baselines are applied to average and relate docking scores with each
individual and class of proteins. A kinase-enriched library (1,451 proteins, 464 transferases, and
65 unique kinases) was assigned for docking with the three compounds. A hit on a protein is
classified as the potential (p value < 0.05) of the molecule of interest to bind to the specified protein
with a theoretical KD of 10 μM or less. This analysis can infer the specificity of a molecule for a
particular class of proteins. The VTS results for each compound are listed in Figure 3.3H.
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The staurosporine control gave an expected baseline commensurate of a pan-kinase inhibitor.
It displayed low to moderate total protein activity with moderately high interaction with general
transferases and hit a majority of kinases, alluding a clear preference for kinases. ICA-1S
demonstrated a low total protein activity with a slight but pronounced increase in affinity for
transferases and kinases. This suggests a possibility of seeing some expected broad kinase
interference for ICA-1S. ζ-Stat, however, portrays significant specificity in VTS. It has similar low
hit percentages for all protein classes, implying little to no expected kinase activity.

3.2.4. Inhibition of cell viability
The effects of ζ-Stat on CCOC cellular viability was investigated via WST-1 methodologies.
The results revealed that 10μM ζ-Stat did not significantly effect SHT290 normal endometrial
stromal cells, but did significantly decreased the viability by 37% in TOV21G cells (p value
0.0436, F = 4.2461, t = -3.058) and by 57% in ES-2 cells (p value 0.00363, F = 7.2918, t = -4.220)
(Figure 3.4A-C). These results suggest that ζ-Stat decreases the viability of CCOC but has
negligible effects on normal endometrial stromal cells.
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Figure 3.4 Cell proliferation and viability of SHT290, TOV21G and ES-2 CCOC cell lines. (A) SHT290, (B)
TOV21G and (C) ES-2 cells were treated for 0, 24, 48 and 72 hrs with 1μM, 3μM, 5μM and 10μM ζ-Stat. WST-1
assays were run after 72 hrs of ζ-Stat treatment (Vehicle control N=12, treatment N=3). A standard curve for each cell
line is also represented. Standard deviation is represented. A one-way ANOVA was tested for the WST-1 assays. (*
p < 0.05, ** p < 0.01).

3.2.5. Analysis of the PKC-ζ/Ect2/Rac1/RhoA pathway
To determine the downstream effects of ζ-Stat on invasion, immunofluorescence, Western
Blots and semi-quantitative endpoint PCR techniques were utilized. Vehicle control and ζ-Stat
treated TOV21G cells were probed with anti-Ect2 and imaged. The results showed that Ect2 was
present in the filamentous extensions in control cell. After treatment, the polarity of the
filamentous extensions decreased and Ect2 was found to be more abundant around the nucleus
(Figure 3.5A-B). Western results demonstrated that 3μM of ζ-Stat decreased RhoA protein
expression as well as mRNA expression (Figure 3.5C-D). These results suggest that the decrease
in PKC-ζ protein expression reduces the expression of RhoA at the genomic level.
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Figure 3.5 Effects of ζ-Stat on Ect2 localization and RhoA protein and genomic expression. (A) TOV21G cells were
seeded on a four-chamber slide and treated for 72 hrs with 10μM ζ-Stat. The slide was fixed with formaldehyde and
immunostained with anti-Ect2, phalldoidin dye, and DAPI. Original magnification is 40X and scale bar is 20μm. (B)
Ect2 is visualized in the filamentous extension of the TOV21G cell. (C) A Western Blot for TOV21G and ES-2 cells
treated for 72 hrs with vehicle control (DMSO) and 3μM ζ-Stat is represented with an immunoblot that was probed
for PKC-ζ and RhoA (N=3). (D) TOV21G and ES-2 cells were treated for 72 hrs with 3μM ζ-Stat and harvested with
RNAbee for mRNA semi-quantification. Endpoint PCR was run with RhoA and GAPDH primers (mRNA control)
(N=3).

Furthermore, Ect2 localization was observed by immunofluorescence with and without
treatment. The PCC showed that the control had a lower amount of Ect2 nuclear localization (0.57)
in comparison to the treated (0.72) TOV21G cells (Figure 3.6A). In contrast, ES-2 cells had little
effect as both the control and the treated cells had a PCC value of 0.69 (Figure 3.6B). In addition,
the filamentous actin (F-actin) organization was investigated via phalloidin stain. In Figure 3.6C,
the F-actin in the control for TOV21G showed filamentous extensions, whereas in the treated cells,
the F-actin seemed to aggregate within the cell, rounding the edges. Although a nuclear
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fractionation could not confirm the translocation of Ect2 into the nucleus is TOV21G cells (Figure
3.6 D), it did show that this translocation did occur in ES-2 cells. An explanation for this may be
that the ζ-Stat is disrupting the cell structure causing the cells to become more globular and thereby
making the cytosol surround the nucleus in a more significant manner.

Figure 3.6 Localization of Ect2. (A) TOV21G and ES-2 cells were probed with anti-Ect2, phalloidin dye and DAPI.
The Pearson’s correlation coefficient is represented in white at the bottom left corner of the merged images. Original
magnification is 40X and scale bar is 20μm. (B) A visualization of the organized filamentous actin in TOV21G cells
treated with vehicle control (DMSO). (C) A visualization of Ect2 localization in TOV21G cells treated with 10μM ζStat for 72 hrs. (D) Nuclear and cytosolic fractionation of TOV21G and ES-2 cells were treated for 72hrs with 10μM
of ζ-Stat, Western blotted and immunoblotted with Ect2. Control antibodies used were β-tubulin (cytosol) and PARP
(nucleus).

Moreover, TOV21G cells were treated with 10μM ζ-Stat and seeded into 96 welled transwell
plates. After 24hrs of treatment, the cells were fixed and stained to determine the effects ζ-Stat on
invasion and migration. Our data showed that ζ-Stat drastically decreased invasion and migration
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when compared to the control (Figure 3.7A). After the images were quantified, the data revealed
that the decrease in invasion and migration was statistically significant (Figure 3.7B&C; invasion
p value 0.002826, t = 4.859; migration p value < 0.001, t = 6.1887). To further illustrate this point,
Rac1 activation was investigated utilizing a GST pull down method. The negative and positive
control display how well the assay data fits the intended model (p value < 0.001, t = 7.675).
Compared to the sample control, the amount of activated Rac1 pulled down from treated samples
was only 37% (p value 0.044, t = -3.044; Figure 3.7D). These data reinforce the theory that ζ-Stat
decreases the invasion and migration of CCOC through a decreased activation of Rac1.

Figure 3.7 PKC-ζ regulates invasion and migration of TOV21G ovarian cancer. (A) TOV21G cells were grown,
serum starved for 48hrs, and placed in the upper chamber of transwell plate coated with 0.1x BME and serum (10%)
containing media was placed in the lower chamber as a chemo attractant. Following treatment with 10μM ζ-stat for
24hrs, cells that invaded through BME and migrated into the lower chamber were stained with crystal violet and
observed under microscope. Original magnification is 10x and scale bar represents1mm. (B) Invasion (N=4) and (C)
migration (N=4) fixed and stained cells on the lower chamber were quantified using ImageJ FIJI software, average
and plotted. Standard deviation error bars are represented. (** p < 0.01, *** p < 0.001). (D) Activated Rac1 (GTP
bound) was pulled down using GST tagged PAK-PBD and analyzed by Western Blot. Densitometry of activated Rac1
bands were plotted (N=4). Standard deviation error bars are represented.
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3.2.6. Analysis of the ζ-Stat in TOV21G tumor xenografts
To determine the effects of ζ-Stat in-vivo, we injected athymic nude female mice with TOV21G
cells and sequentially treated mice for 35 days. At the endpoint of the experiment, the tumors were
harvested, and the blood serum was screened for enzymes associated with kidney and liver failure,
as well as glucose levels for screening diabetes. Our data exhibited statistically significant changes
in tumor volume between vehicle control and treated mice (Figure 3.8A) starting on day 14 (p
value 0.006343, t = 3.4389) up until day 35 (p value 0.001136, t = 4.4827). Results also
demonstrated that ζ-Stat decreased tumor growth by more than 50% by the endpoint of the
experiment (Figure 3.8B-C) and decreased PKC-ζ and RhoA expression in tumors by more than
40%. The treatments did not lower the mouse population’s body weight (Figure 3.8D) and did not
have a significant effect on the enzyme panel (Figure 3.8E-F). These preliminary results suggest
that ζ-Stat can be used for the treatment of CCOC and does not cause short-term toxicity.
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Figure 3.8 Effects of ζ-Stat on in-vivo xenografts with athymic nude mouse models. (A) Six vehicle control mice and
six treatment mice were injected with 1 x 106 cells/per mouse flank in 0.2mL of media of TOV21G CCOC cells.
Vehicle control mice tumors were treated with 1x DPBS and treatment mice were treated with 20mg/kg of ζ-Stat.
Tumors were measured every other day and plotted. An unpaired student T test was performed, and standard deviation
error bars are presented (* p < 0.05, ** p < 0.01). (B) Tumors were harvested after 35 days of treatment and a picture
was taken. Tumors were fractionated and protein lysates were run via Western blot. Analysis of the protein expression
of PKC-ζ and RhoA were investigated. Β-actin was used as a control. Densitometry of the results are represented in
bar graph as expression percent of the control with standard deviation error bars. (C) Endpoint treated tumor volumes
were graphed as a percent of the control (D) Mouse weight was recorded once per week. An unpaired student T test
was performed, and standard deviation error bars are presented (no significant difference observed). (E-F) Endpoint
blood serum was taken and screened for glucose (GLU), blood urea nitrogen (BUN), alanine aminotransferase (ALT),
aspartate aminotransferase (AST) and alkaline phosphatase levels for toxicity. An unpaired student T test was
performed, and standard deviation error bars are presented (no significant difference observed).

3.2.7. ζ-Stat interrupts the PKC-ζ/Ect2 via PKC-ζ protein decrease
Our predicted pathway models that PKC-ζ scaffolds Ect2 to the cellular membrane (Figure
3.9). This mis-localization of Ect2 permits the wild-type Ect2 more access to Rac1 and therefore
increases its activation. Upon increased Rac1 activation, CCOC invasion is increased. PKC-ζ
protein level decrease via ζ-Stat, releases Ect2 from the membrane scaffold, and re-localizes Ect2
to the nucleus, limiting its access to cytosolic Rac1 and decreasing Rac1 activation.
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Figure 3.9 ζ-Stat decreases the amount of PKC-ζ, therefore decreasing the scaffold of Ect2 in the cytoplasm. The
hypothesized pathway illustrates the scaffolding of Ect2 via PKC-ζ in the cytoplasm. Treatment with ζ-Stat decreases
PKC-ζ expression thereby there is less PKC-ζ to bind Ect2, allowing Ect2 to re-localize to the nucleus. This decreases
Ect2 cellular access to Rac1, reducing Rac1 activation and cell migration.
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3.8. Supplemental figures

Figure S3.1 RMSD (Bottom) of backbone atoms and Radius of Gyration (Rg, Top) of all atoms graphs for PKC-ι
Molecular Dynamics simulation. Equilibration appears to occur after 7 ns with an average RMSD of 2.3Å.
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Figure S3.2 RMSF (Root Mean Square Fluctuation) plot of PKC-ι Molecular Dynamics simulation. Graph shows
the RMSD per residue of α-carbon over length of simulation. Most displacements are under 2Å aside from tail
regions and chain discontinuities from missing residues 446-454.
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Figure S3.3 RMSD (Bottom) of backbone atoms and Radius of Gyration (Rg, Top) of all atoms graphs for PKC-ζ
Molecular Dynamics simulation. Some asymptotic behavior does appear to occur, however, an average RMSD of
4.5Å and increasing Rg implies unfolding and significant deviation from any structural energetic minimum.
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Figure S3.4 RMSF (Root Mean Square Fluctuation) plot of PKC-ζ Molecular Dynamics simulation. Graph shows
the RMSD per residue of α-carbon over length of simulation. The ATP region, approximately residues 300-450,
show displacements under 2Å. Most homologous residues show RMSD values well above 2Å.
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Figure S3.5 Raw Western blot images for TOV21G and SHT290 Figure 3.2A. (A) Western blot of PKC-ι in
TOV21G and SHT290 cells at 50% and serum free (SF). (B) Western blot of PKC-ζ in TOV21G and SHT290 cells
at 50% and serum free (SF). (C) Western blot of β-actin in TOV21G and SHT290 cells at 50% and serum free (SF).
Rows 3 and 4 were used for the TOV21G image and rows 7 and 8 were used for the SHT290 image.

Figure S3.6 Raw Western blot images for ES-2 Figure 3.2A. (A) Western blot of PKC-ι in ES-2 cells at 50% and
serum free (SF). Bands are loaded in the opposite order. (B) Western blot of PKC-ζ in ES-2 cells at 50% and serum
free (SF). Bands are loaded in the opposite order. (C) Western blot of β-actin in ES-2 cells at 50% and serum free
(SF). Bands are loaded in the opposite order.
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Figure S3.7 Raw Western blot images for TOV21G Figure 3.2B. (A) Western blot of PKC-ι and its corresponding
β-actin in TOV21G cells. (B) Western blot of PKC-ζ and its corresponding β-actin in TOV21G cells.

Figure S3.8 Raw Western blot images for ES-2 Figure 3.2B. (A) Western blot of PKC-ι and its corresponding βactin in ES-2 cells. (B) Western blot of PKC-ζ and its corresponding β-actin in ES-2 cells.
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Figure S3.9 Raw Western blot images for TOV21G Rac1 PD utilizing GST PAK-PBD Figure 3.7D. (A) Western
blot of Rac1 exposure time of 1 minute. Rows 1 and 2 are the positive and negative control, respectively. (B)
Western blot of Rac1 exposure time of 2 minutes. The positive control is saturated (marked in pink). Rows 5 and 6
are the vehicle control and 10μM treatment for TOV21G cells.

Figure S3.10 Raw Western blot images for TOV21G RhoA and PKC-ζ protein decrease (A) Western blot of RhoA
in TOV21G cells with vehicle control (Row 2) and 3μM treatment (Row 3). (B) Western blot of PKC-ζ in TOV21G
cells with vehicle control (Row 2) and 3μM treatment (Row 3). (C) Western blot of β-actin in TOV21G cells with
vehicle control (Row 2) and 3μM treatment (Row 3).
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Chapter 4: Discussion and future directions

4.1 Role of PKC-ζ in breast cancer
4.1.1

PKC-ζ expression was higher in invasive tissue subtypes

Previously, Yin et al. showed that the expression of PKC-ζ was higher in invading breast tissues
compared to samples uncomplicated with tumors and the highest PKC-ζ protein expression existed
in stage III human breast ductal carcinomas 78. Likewise, Paul et al. concluded that the depletion
of PKC-ζ reduced the invasive behaviors of MDA-MB-231 cells by upregulating epithelial
markers such as Zonula occludens-1 (ZO-1) and E-Cadherin

14

. They also found that PKC-ζ

activation (phosphorylated PKC-ζ levels) was found higher in invasive tissues (i.e. IDC and
metastatic tissues) when compared to non-invasive tissues (DCIS). PKC-ζ expression did not
significantly change with the presence or absence of receptors (ER and HER2)14. Our Western
Blots and Chi-squared analysis (Figure 2.1A, 2.1B, Table 2.3B) support these findings. They
performed a PKC-ζ knockdown mouse study and found that the depletion of PKC-ζ leads to an
approximately 50% reduction in primary tumor growth compared to the control within five weeks
14

. Similarly, our Western Blot analysis and immunohistochemistry data of IDC and ILC (Figure

2.1A-C) suggest that PKC-ζ might also be a novel component in pathways that affect cancer cell
invasion and metastasis.
PKC-ζ assists a transcription factor (NFκB-p65) that downregulates targets such as E-Cadherin
and ZO-1 14. In addition, decreased E-Cadherin levels cause the cells to no longer adhere to the
53

extracellular matrix causing the cells to migrate, invade, or metastasize 14. Moreover, H.L. Chua
et al. showed that NF-κB induced elevated expression of Zinc finger E-box binding homeobox 1
and 2 (ZEB-1 and ZEB-2) which ultimately repress the E-Cadherin levels 49. In our investigation,
we could not establish a statistical relationship between PKC-ζ and E-Cadherin protein expression
in IDC (Figure 2.2B) as per the linear regression analysis. However, previous studies illustrated
an increase in E-Cadherin levels in PKC-ζ knockdown MDA-MB-231 cells 14.

4.1.2

PKC-ζ expression was higher in ductual carcinomas when compared to lobular

carcinomas
In addition, our findings showed an increased expression of PKC-ζ in IDC tissues when
compared to other subtypes (Figure 2.1A-C) which may be because of the difference in
pathological features of ductal and lobular tumors. Ductal carcinomas are lined with a two-layered
stratified cuboidal epithelium resting on the basement membrane. This cuboidal epithelium
contains tight junctions where E-Cadherins are located and play a central role in cell-to-cell
adhesion

79

. In contrast, lobular carcinomas vary in terms of molecular and genetic aberrations

compared to ductal carcinomas. Lobular carcinomas are epithelial-like, growing individually in
sheets or in a single file

12

. In our investigation, E-Cadherin levels were also compared to the

nuclear grade listed on the pathology report (Figure 2.2C, Table 2.3C), which suggest the
previous studies that described a decline in E-Cadherin as a part of the epithelial to mesenchymal
transition leads to metastasis 49,80.
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4.1.3

PKC-ζ knockdown decreased cellular migratory behaviors

During metastasis, directional cell movement involves five distinct steps: leading edge
membrane protrusion, adhesion of the protrusion to the substrates, cell body translocation, deadhesion of the tail from the substrate and trailing edge retraction 81. These processes are mainly
controlled by reorganization of the actin in the cell cytoskeleton which in turn are regulated by
GTPases (Guanosine Triphosphatases)82. Among the GTPases, RhoA, Rac1, and Cdc42 are most
commonly studied because of their crucial role in actin assembly and formation of metastatic
structures of cells, such as filopodia, lamellipodia and stress fibers

36

. Rac1 and Cdc42 produce

localized actin polymerization at the leading edge which pushes the membrane forward in slender
like structure known as filopodia and sheet-like structure known as lamellipodia that ultimately
generate locomotive force in migrating cells

83

. In contrast, RhoA promotes the assembly of

contractile actomyosin filaments and acts on the rear end of the migrating cells, inducing tail
detachment

34

. Thus, Rac1 and Cdc42 stimulate leading edge protrusion, and RhoA stimulates

trailing edge retraction in metastatic cells. We found that the knockdown of PKC-ζ by siPRKCZ
reduced the invasion of MDA-MB-231 breast cancer cells by 60% (p < 0.05) when compared to
control (Figure 2.3A, 2.3B). In addition, there was a decreased expression of both Rac1 and RhoA
in siPRKCZ transfected MDA-MB-231 breast cancer cells compared to control (Figure 2.3C).
Furthermore, our immunostaining analysis of F-actin illustrated that actin filaments were nicely
organized around the cells with the inhibition of PKC-ζ (Figure 2.4). Hence, PKC-ζ may play an
essential role in the invasion and migration of breast cancer cells by the regulation of RhoA and
Rac1 pathways.
To conclude, our findings suggest that PKC-ζ is found to be most abundant in invading tissue
subtypes and may be a functional component of invasion pathways such as Rac1 and RhoA. The
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use of PKC-ζ-specific inhibitors could be used to correlate the decrease in expression or
functionality of PKC-ζ with the decrease in invasive behavior in breast cancer.

4.2 ζ-Stat as a novel inhibitor in ovarian cancer
In this study, we discovered that the small molecule inhibitor, ζ-Stat, is a prospective drug
candidate to investigate as a novel potential treatment for CCOC. We also investigated the PKCζ/Ect2/Rac1 activation pathway and found that ζ-Stat decreases the invasive behavior of CCOC
by decreasing cytosolic Ect2 and Rac1 activation.

4.2.1

Targeting aPKCs in CCOC

To understand the therapeutic potential of a protein target, there must be an appreciation of the
underlying genetic abnormalities specific to the cancer type. The TP53 gene (tumor suppressor
p53) is the most commonly mutated gene in all ovarian cancers and is especially a prognostic
marker of HGSOC 84. In contrast, CCOC typically has a wild type TP53 and mutations in the tumor
suppressor ARID1A 85. Although PRKCZ and PRKCI are not in the top mutated genes in CCOC,
PIK3CA is mutated (~30%) and is located on the third chromosome’s long arm. Interestingly,
PIK3CA (3q26.32), ECT2 (3q26.31) and PRKCI (3q26.2) are all located on the long arm of
chromosome three and in proximity. The ARID1A (1p36.11) is also located up stream of PRKCZ
(1p36.33) on the short arm of the first chromosome. It has been noted that mutations and
deficiencies in ARID1A have been shown to sensitize cancers to PARP and PI3K inhibitors
(Figure 4.1) 86–88.
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Figure 4.1 PIK3CA and ARID1A mutations in clear cell ovarian carcinoma. PIK3CA and ARID1A are commonly
mutated in CCOC. When ARID1A is not mutated, it indirectly inhibits and regulates the PI3K pathway. ARID1A
mutations increase the upregulation of the PI3K pathway, typically through loss of function via truncation of protein
translated.

Previous literature has suggested that the atypical PKCs and their pathways should be the focus
of targeted treatment
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. One explanation for this is that the atypical PKC isoforms have been

linked to signaling pathways needed for cancer survival and growth. A study performed by Yao et
al. illustrated the dramatic changes to prostate cells malignancy upon PKC-ζ silencing 30. In our
study, when CCOC (TOV21G and ES-2) cells grew rapidly and were cell cycle arrested (serum
starved), the aPKCs were present in both conditions. However, the expressions of PKC-ζ and PKCι were found to be very low in the normal endometrial stromal cells. These findings may indicate
that CCOC cells have a reliance on aPKC overexpression for cell viability. An interesting
complication in other types of CCOC is that ζ-Stat does not specifically limit expression of PKCζ but also effects downstream targets in the PKC-ζ/Ect2/RhoA pathway. As shown in Figure 3.2,
ζ-Stat had a negligible effect on PKC-ζ expression in ES-2 cells, however in Figure 5, there was a
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decrease in RhoA protein and mRNA expression. This leads to the conclusion that ζ-Stat has
generalized effect on the pathway dependent on cell type. Furthermore, these data support that
PKC-ζ/Ect2/RhoA pathway contains relevant targets for CCOC due to the lack of overexpression
in normal tissue and the overexpression in cancerous cell lines.
Equally important, a previous study showed that the knock down of PKC-ζ using siRNA
decreased the expression of RhoA and Rac1 13. Furthermore, this study illustrated that the knock
down of PKC-ζ decreased the invasive behavior of breast cancer cells by more than 40%. Our data
supports previous data and reiterates the therapeutic potential for targeting PKC-ζ in CCOC.

4.2.2

aPKCs are involved in the localization of Ect2

The mis-localization and overexpression of Ect2 has been linked to aPKCs and Ect2 dependent
malignant transformation 89. Cytoplasmic Ect2 has more access to Rho GTPases and increases the
protein family’s activation. Liu et al. identified Ect2 as an activator of the Par6/Par3/aPKC polarity
complex and further showed that Ect2 stimulated PKC-ζ activity

32

. Moreover, the oncogenic

activity of Ect2 was shown to be regulated by aPKC via the phosphorylation of the Thr 328 site
and a mutation in this site (T328A) rendered the Ect2 unable to interact with Par6/aPKC complex
or activate Rac1 15. Upon treatment with ζ-Stat, the decrease of PKC-ζ disturbs the localization of
Ect2 in TOV21G cells. This specific effect is not seen in ES-2 as correlations are equal before and
after ζ-Stat treatment. Therefore, it does not seem that PKC-ζ is the specific target but more of the
generalized PKC-ζ/Ect2/RhoA pathway.

4.2.3

ζ-Stat has therapeutic potential in CCOC
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A common treatment regime for ovarian cancer patients typically involves chemotherapy
(paxitaxol), PARP (poly ADP ribose polymerase) inhibitors and bevacizumab (targets
angiogenesis) 62. However, concerns for current treatments still involve toxicity, drug-resistance,
reoccurrence and the side effects to the patients 90. Our data showed that mice treated with ζ-Stat
did not have significant side effects when compared to mice treated with the vehicle control. In
particular, the mice did not have significant fluctuations in body weight, or differences in the
enzyme panel which screened for liver and kidney damage. Further, the viability of normal
endometrial stromal cells did not change significantly upon treatment of 10μM ζ-Stat. All these
data support the prospect that this compound may be a less toxic alternative maintenance drug for
CCOC.
The presence of PKC-ζ and PKC-ι in proliferation, invasion and migration make this protein a
unique target for therapies. In the previous literature, ζ-Stat was shown to decrease the invasion
and migration of melanoma cells and increase apoptosis 20. It has also been suggested the ζ-Stat is
selective to PKC-ζ in melanoma and colorectal cell lines 10, 20,91. In support of the previous data,
our data showed that ζ-Stat had a dramatic effect on CCOC invasion and migration.
However, new evidence supports the theory that ζ-Stat does not inhibit kinase activity of PKCζ through the ATP binding region. Our computational and in-vitro data advocates that ζ-Stat
decreases the expression of signaling proteins (PKC-ζ and RhoA). This phenotypic effect
consistently modifies kinase interaction networks which results in decreases in cellular viability,
invasion and tumor growth 10,20. The effects that ζ-Stat elicited was decreased PKC-ζ protein, relocalized Ect2 to the nucleus and decreased the presence of activated Rac1. ζ-Stat specifically
decreased the protein expression of PKC-ζ in comparison to PKC-ι, however this mechanism is
still unknown. The data suggests that ζ-Stat may be generating an epigenetic effect, which in turn
59

regulates the expression of these proteins. It has been suggested that using aPKC inhibitors can
epigenetically regulate the expression of aPKCs through transcription factors, such as FOX01 92.
Additionally, according to the computational data, ICA-1S exhibited poor binding with the
PKC-ι and PKC-ζ ATP site and had a predicted moderate affinity with a possible PKC-ι allosteric
site. This fits well with previously performed MBP phosphorylation experiments

20

. Some

expected kinase activity with mid-range binding promiscuity is anticipated for this molecule.
However, this conclusion is contradicted by some evidence from the experiment, therefore it could
simply be that the generated PKC-ζ model is insufficient for correlating physical data. ζ-Stat
exhibits extremely poor binding with the ATP site and PKC-ι allosteric site. With no expected
kinase activity and low binding promiscuity, any inhibition seen using ζ-Stat is likely specific for
unique binding pockets.
To further the exploration of ζ-Stat being a potential therapeutic for CCOC, a mechanistic
understanding of the direct protein binding is required for PKC-ζ and PKC-ι.

4.3 Future directions
In future research, PKC-ζ should continue to be a focus and target for molecular therapies,
especially in breast and ovarian cancers. The small molecule inhibitors ICA-1 and ζ-Stat should
be further investigated for its pre-clinical significance in-vivo and absorption, distribution,
metabolism and excretion studies. In addition, to further validate the in-silico results, direct
binding studies of these small molecule inhibitors should be performed with PKC-ι and PKC-ζ
protein to have a better mechanistic understanding of where and how the small molecules are
binding.
60

Chapter 5: Materials and Methods

5.1. Analysis of PKC-zeta protein levels in normal and malignant breast tissue subtypes
5.1.1. Specimen collection and tissue fractionation
The NCI-supported Cooperative Human Tissue Network (Birmingham, Alabama) collected
and provided the breast tissue samples (normal, LCIS, ILC, DCIS, and IDC). The specimens were
collected and snap-frozen in liquid nitrogen or placed in dry ice and stored in a liquid nitrogen
vapor phase freezer (-196 °C), where the tissues stayed until shipment. The tissues were shipped
in dry ice. Formalin-fixed paraffin-embedded tissues (FFPE) were also provided for
immunohistochemistry staining. Tissues were selected based on their histological features
(normal, LCIS, ILC, DCIS, and IDC). The mean age of patient samples collected was 51 years and
the collection period of the samples was 2001-2015. Normal tissues were selected from breast
reduction patients with no previous diagnosis of cancer or the area adjacent to a patient’s malignant
tumors. Patients with DCIS and LCIS were selected based on the lack of invasive tissue adjacent
to the extraction site; some tissues were taken from patients with invasive tissues in the opposite
breast.
The tissue specimens were then resuspended and sonicated for 3 x 5 sec cycles on ice in 1 mL
of homogenization buffer (Pierce® Immuno Precipitation Lysis Buffer, 25 mM Tris-HCl pH 7.4,
150 mM NaCl, 1 mM EDTA, 1% NP-40 and 5% glycerol, Thermo Fisher Scientific, MA),
followed by, centrifugation at 12,879 x g for 15 mins at 4°C to obtain cell extracts. Subsequently,
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250 µL of albumin removal resin (Pierce™ Albumin Depletion Kit, Thermo Fisher Scientific,
Waltham, MA, USA) was added to the lysate and left at 4°C overnight. The samples were further
centrifuged at 12,879 x g for 15 mins at 4°C, the supernatant was subsequently collected, and
protein content was measured according to Pierce® 660 nm Protein Assay reagent protocol
(Thermo Fisher Scientific, Waltham, MA, USA) and NanoDrop 2000.

5.1.2.

Cell culture

The metastatic breast cancer cell line, MDA-MB-231 was obtained from American Type
Tissue Culture Collection (ATCC, Manassas, VA, USA). The MDA-MB-231 cells were subcultured and maintained in T75 flasks containing Dulbecco’s Modified Eagle’s Minimum media
(DMEM), supplemented with 10% FBS (Fetal Bovine Serum) and 1% antibiotics (Penicillin 10
U/ml and streptomycin 10 mg/ml). Cells were incubated at 37oC and 5% CO2. Cells were used at
70-80% confluency for the experiments.

5.1.3.

Western Blot analysis

Like tissue lysates, MDA-MB-231 cell extracts were also prepared after the addition of cell
lysis buffer, sonication, and centrifugation (at 12,879 x g for 15 minutes at 4°C). For Western Blot
analysis, an equal amount (20-30µg) of protein from tissue and cell lysates were loaded in 10%
polyacrylamide gels and separated by using sodium dodecyl sulfate-polyacrylamide gel
electrophoresis (SDS-PAGE). The proteins were then transblotted onto a 0.4µM nitrocellulose
membrane. Subsequently, the membranes were incubated with 5% milk blocking solution,
followed by, primary solution of anti-PKC-ζ (SC-17781, 1:1000, Santa Cruz Biotechnology,
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Dallas, TX; and 9372s, 1:1000, Cell Signaling Technology, Danvers, MA), anti-E-Cadherin
(701134, 1:1000, Invitrogen, Carlsbad, CA), anti-RhoA (ab54835, 1:4000, Abcam, Cambridge,
UK) and anti-Rac1 (4651s, 1:1000, Cell Signaling Technology, Danvers, MA) in 5% BSA (Bovine
serum albumin). Finally, the membranes were incubated with secondary antibodies. All the
secondary antibodies (anti-rabbit and anti-mouse) were obtained from Bio-Rad Laboratories
(#170-6515 and #170-6516, 1:2000, Hercules, CA). The immunoreactive bands were then
visualized by chemiluminescence reaction, according to the manufacturer’s instructions
(SuperSignal™ West Pico PLUS Chemiluminescent Substrate, Thermo Fisher Scientific,
Waltham, MA, USA). A monoclonal antibody to β-actin (SC-1616, Santa Cruz Biotechnology,
Dallas, TX) was used as a loading control.

5.1.4.

Densitometry

The densitometry was performed using Image J (NIH) software by the subtraction of
background noise from the density of each band to derive the corrected intensity. All samples were
normalized based on the intensity of β-actin bands on each blot.

5.1.5. Immunohistochemistry
FFPE tissues received from CHTN were sent to the Tissue Core at Moffitt Cancer Center,
Tampa, FL. Two different patient tissues were selected for each subtype (normal, LCIS, ILC,
DCIS, and IDC) based on the criteria mentioned previously, with a total N=10. Briefly, tissues
were stained with Haemotoxylin and Eosin (H&E), and PQC (pathology quality control) were
performed by Tissue Core pathologist to confirm breast tissue subtype and diagnosis. The slides
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were prepared and stained with antibodies for PKC-ζ (ab59364, 1:1000, rabbit polyclonal, Abcam,
Cambridge, UK). A uterine carcinoma specimen was selected as a positive control based on
antibody data sheet and the Human Protein Atlas recommendations. Slides were stained using a
Ventana Discovery XT automated system (Ventana Medical Systems, Tucson, AZ) as per the
manufacturer's protocol with proprietary reagents. Briefly, slides were deparaffinized on the
automated system with EZ Prep solution (Ventana). The heat-induced antigen retrieval method
(CC1 standard) was used with PKC-ζ (Ventana). The primary rabbit antibody that reacts to human
was used at a 1:1000 concentration in Dako antibody diluent (Carpenteria, CA) and incubated for
32 mins. The Ventana OmniMap Anti-Rabbit Secondary Antibody was used for 16 mins. The
detection system used was the Ventana ChromoMap kit and slides were then counterstained with
Hematoxylin. Slides were subsequently dehydrated and cover-slipped as per normal laboratory
protocol. The Moffitt Tissue Core pathologist selected the optimal condition, titration, and
incubation time to be used on control and the breast selected slides. Subsequently, the pathologist
evaluated the slides using the combinative semi quantitative scores (score 0-3)93. Images were
taken on a light microscope Olympus BX51.

5.1.6. Knockdown of PKC-ζ for invasion pathway analysis
Human breast cancer cells MDA-MB-231 were grown in 100mm plates and transfected with
20nM of scrambled RNA and siPRKCZ (5‘-GCAUGAUGACGAGGAUAUUGACUGG-3’,
SR303747A, Origene, Rockville, MD, USA) for 48 hours. Cells were lysed as previously
described and the lysates were run on Western Blots.
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5.1.7.

Cell invasion assay by crystal violet staining of invaded cells

Cells were serum starved for 24 hours, followed by detachment and plating into the upper
chamber of a 96 wells 8μm Transwell permeable support (Corning Inc., Corning, NY), coated with
0.5x basement membrane extract (BME) (Corning Inc., Corning, NY) for the evaluation of
invasion. Serum (10%) containing media was loaded into the receiver plate (lower chamber) as a
chemoattractant. MDA-MB-231 cells at the upper chamber were transfected with 20nM siPRKCZ
for 24 hours. Four experimental treatment groups for the cells were performed: control (nontreated), Si-Tran (transfection reagent), scrambled siRNA (random RNA) and siRNA for PRKCZ
(for knockdown of PKC-ζ protein expression). The cells were treated with the transfection reagent
(Si-Tran) and universal scrambled RNA to establish the effect of targeted small interfering RNA
(siPRKCZ) only. The invasive cells that passed into the lower chamber were then fixed with 4%
paraformaldehyde, stained with 2% crystal violet in 2% ethanol, washed with distilled water and
photographs were captured after drying using a light microscope Motic AE31E.

5.1.8.

Phalloidin staining of F-actin

Human breast cancer cells MDA-MB-231 (1 x 104 cells) were grown in 2 wells chamber slides,
followed by transfection with 20nM universal scrambled RNA and siPRKCZ for 24 hours. In
addition, cells were also evaluated with the transfection reagent and without any treatment to
establish the targeted effect of PKC-ζ knockdown. Fixation was performed with 4%
paraformaldehyde. F-actin was subsequently stained with 1X Phalloidin-iFluor 594 (Abcam,
Cambridge, UK) in 1% bovine serum albumin (BSA)-phosphate buffered saline (PBS) solution
for an hour at room temperature. Cells were washed, counterstained with the nuclear stain 4′,6-
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diamidino-2-phenylindole (DAPI) (Invitrogen Inc., Carlsbad, CA) and examined under Nikon
MICROPHOT-FX fluorescence microscope (Ex/Em = 590/618). Photographs were captured using
ProgRes®Capture 2.9.0.1.

5.1.9.

Statistical analysis

The statistical significance of the Western Blot data was evaluated by a Student’s t-test (normal
N=32; LCIS N=3; ILC N=13; DCIS N=6; IDC N=29; overall N=83 at p < 0.05; standard error
represented) and the linear regression test (N=20; R2 value) with GraphPad software 94. A one-way
ANOVA was also used to evaluate the Western Blot data as well with the post-hoc Tukey’s HSD
test (p < 0.01), Scheffé multiple comparison (p < 0.05), Bonferroni (p < 0.01) and Holm (p < 0.01).
The contingency table Chi-squared statistical analysis (normal N=32; LCIS N=3; ILC N=13; DCIS
N=6; IDC N=29; overall N=83 at p < 0.00001) for the expression of PKC-ζ and breast subtype was
performed using the Chi-Squared Test Calculator from Social Science Statistics
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. Clinical

parameters such as estrogen receptor expression and Scarff-Bloom-Richardson grade ( presented
in the pathology reports) were also investigated with this statistical software (N=30 and N=22,
respectively). A one- way ANOVA was used to analyze the number of cells invaded after crystal
violet staining; the statistical test was significant at a p value of < 0.05.

5.2. The atypical Protein Kinase C small molecule inhibitor ζ-Stat, and its effects on invasion
through decreases in PKC-ζ protein expression

5.2.1. Antibodies and reagents
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The small molecule inhibitors, ζ-Stat and ICA-1S, were obtained from the National Institute
of Health (NIH) branch National Cancer Institute (NCI) and United Chem Resources in
Birmingham Alabama, respectively. The sources of cell lines, reagents and antibodies were:
TOV21G and ES-2 CCOC cell lines (American Type Culture Collection, USA); SHT290 normal
endometrial stromal cell line (Kerafast, USA); MCDB 121, Media 199, F12K, penicillin and
streptomycin, trypsin, Dulbecco’s phosphate buffered saline (DPBS) and Mito + (Corning, USA);
McCoy’s media (HyClone, USA); Opti-MEM I (Gibco, USA); Fetal bovine serum (FBS, Atlanta
Biologicals, USA); human insulin (MP Biomedicals, LLC, France); dimethyl sulfoxide (DMSO,
Sigma Aldrich, USA); Water-Soluble Tetrazolium (WST-1, Roche, USA); Halt protease and
phosphatase inhibitors cocktail and Protein A/G magnetic beads (Thermo Scientific, USA); antiPKC-ζ (9372s, 1:1000, Cell Signaling, USA); anti- PKC-ι (610178 1:1000, BD, USA); anti-βactin (A3854, 1:40000, Sigma Aldrich, USA); anti-RhoA (ab54835,1:4000, Abcam, USA); antiEct2 (07-1364, 1:1000, Millipore, USA); anti-β-tubulin (5346t, 1:1000, Cell Signaling, USA);
anti-PARP (9532s, 1:1000, Cell Signaling, USA); Donkey anti-rabbit IgG Alexa-488 (A21206,
1:500, Invitrogen, USA) ; Goat anti-rabbit (170-6515, 1:2000, Bio-Rad Laboratories, USA); Goat
anti-mouse (170-6516, 1:2000, Bio-Rad Laboratories, USA); Activated Rac1 pulldown kit
(BK035, Cytoskeleton, USA); 96-well transwell insert and basement membrane extract (BME;
both Corning Inc., Corning, NY, USA); RNA bee (Amsbio, United Kingdom); Qiagen RT Kit (
205113, Qiagen, Germany); RhoA PCR primers (HP100025, Sino Biological, USA);
Glyceraldehyde 3-phosphate dehydrogenase (GAPDH) PCR primers (Eurofins, USA); NE-PER
Nuclear and Cytoplasmic Extraction Reagents (78835, Thermo Fisher Scientific, USA).

5.2.2. Analysis of somatic gene mutations for ovarian cancer, CCOC and CCOC cell lines
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The selection of CCOC cell lines employed the COSMIC database 67. Initially, the search was
focused on all ovarian subtypes in the database. The search was then re-focused on clear cell
carcinomas. Furthermore, the COSMIC cell line project was utilized for the analysis of mutations
in TOV21G and ES-2 cells 67.

5.2.3. Computational analysis of aPKCs
5.2.3.1.

Protein preparation

Protein model systems for PKC-ι and PKC-ζ were prepared using the Schrodinger software
suite 96. Protein structure coordinates were downloaded from the Protein Data Bank (PDB) 97,98.
The PKC-ι model was generated from the PDB 3A8W entry co-crystallized with adenosine
triphosphate (ATP) 68. The apo structure, PDB 38AX, was used to cross reference conformational
states from Molecular Dynamics (MD) simulations. No crystal structure currently exists of PKCζ, necessitating the need for homology modeling to attempt to produce a potentially viable docking
model for PKC-ζ. Two PKC-ζ models were built, one utilizing SWISS-MODEL 73–75 and another
employing the Prime homology program 69–71 using the human PKC-ζ sequence (UniProt Q05513)
and the crystallized PKC-ι structures as templates. PDB systems were prepared with the Protein
Preparation Wizard (PrepWizard) in Maestro

71,99–102

. Cofactors used in crystallization (such as

sulfate or phosphate ions), ligands, and additional protein dimers were deleted. Bond orders were
then assigned, including disulfide bridges, and original hydrogens were deleted and later replaced
to reduce bad contacts and other crystal artifacts before protonation and hydrogen bond
optimization. All waters were retained for assisting in the determination of side chain protonation
states and initial hydrogen bond optimization. Missing side chains were added and optimized using
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Prime. Hydrogen atoms were then added to the protein, remaining cofactors, and to any added
structural waters. The program PROPKA 103 was used for the prediction of protein ionization states
at 7.4 pH and ProtAssign was used for hydrogen bond optimization. After automatic hydrogen
assignment, visual inspection was used to flip residues and change protonation states at proteinprotein interfaces if and when appropriate.

5.2.3.2.

Molecular dynamics

MD simulations were performed with the Desmond MD program

104–107

. A cubic simulation

box was created extending at least 10Å from the protein with imposed periodic boundary
conditions. TIP3P waters
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were added to solvate the simulation box and was then electrically

neutralized by introducing sodium ions. The OPLS-3 all-atom force field 109 was then applied to
all atoms. The SHAKE algorithm

110

was used to constrain all bonds in the system and the

REference System Propagator Algorithm (RESPA)

111

with an integration time step of 2 fs was

employed. The Particle Mesh Ewald (PME) algorithm was used to calculate long-range
electrostatics with a real-space cutoff of 13 Å. Van der Waals interactions were cutoff at 16 Å. The
systems were simulated in an NPT ensemble using the Nose−Hoover temperature coupling scheme
112

at a temperature of 310 K and a constant pressure of 1 atm using the Martyna-Tuckerman-

Tobias-Klein (MTTK) barostat 113,114.
All systems were energy minimized with a truncated newtonian conjugate gradient (TNCG)
method

115

followed by multiple restrained minimizations to randomize systems before

equilibration and final simulation. Heavy atoms of the protein were held fixed during heating for
an initial 12 ps NVT ensemble simulation at 10 K with the Berendsen thermostat
69

116

. This was

followed by simulations at 1 atm in the NPT ensemble for 12 ps at 10 K and 24 ps at 310 K.
Unrestrained equilibration MD was then performed for 24 ps at 310 K and 1 atm. Finally,
unconstrained production MD was performed on PKC-ι and PKC-ζ systems for 250 ns. Energies
were recorded every 2 ps and trajectory frames were recorded every 5 ps.
Final system equilibration was determined by the observation of asymptotic behavior of the
potential energy, Root Mean Square Deviation (RMSD), and Radius of Gyration (Rg) profiles and
visual inspection of trajectories guided by Root Mean Square Fluctuation (RMSF) profiles
(Supplementary Material).

5.2.3.3.

Consensus docking

After equilibration was determined, a hierarchical average linkage clustering method based on
RMSD was utilized to determine an average representative structure for the equilibrated PKC-ι
system. The program PROPKA was then implemented again on the equilibrated structure to test
consistency of side chain protontion states at 7.4 pH. The representative structure was then used
for consensus docking incorporating five diverse and complimentary docking methods described
below. By applying these varied energy scoring methods, the weaknesses of each method can be
identified for a particular model and error statistically minimized, yielding a more accurate
summary of ligand binding dispositions and affinities.
As a check for the placement of the grids used in the docking studies and for further analysis
of the binding cavities for the ATP binding site and the potential allosteric site, Schrödinger's
SiteMap program 117–119 was employed. SiteMap searches the protein structure for likely binding
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sites and highlights regions within the binding site suitable for occupancy by hydrophobic groups,
hydrogen-bond donors, acceptors, or metal-binding functionality of the ligand.
The ligands ICA-1S, ζ-Stat, and ATP were prepared using the program LigPrep

120

and the

OPLS-3 all-atom force field was applied to all ligand atoms.

5.2.3.4.

Rigid receptor docking (RRD)

Rigid docking simulations were performed by Glide

121–123

. Glide uses a GlideScore fitness

function based on Chemscore 124,125 for estimating binding affinity, but includes a steric-clash term,
adds buried polar terms to penalize electrostatic mismatches, and modifies other secondary terms.
Docking simulations used both the standard precision (SP) and extra precision (XP) methods. XP
mode is a refinement algorithm enforced only on good ligand poses. Sampling is based on an
anchor and refined growth strategy and the scoring function includes a more complete treatment
of some of the SP energetic terms, such as the solvation and hydrophobic terms. Docking grids
were defined by a rectangular ligand atom inclusion outer box of 22Å and ligand centroid
constraint inner box of 10Å in the x, y, and z directions originating from the binding cavity centroid
defined by SiteMap for the proposed allosteric site and by the original co-crystallized ATP ligand
centroid for the ATP binding site.

5.2.3.5.

Induced fit docking (IFD)

The IFD methodology 71, 123,126–128 incorporates both the docking program Glide to account for
ligand flexibility and the Refinement module in the Prime program to account for receptor
71

flexibility. The Schrödinger IFD protocol attempts to model induced-fit effects from alterations in
binding site conformation due to ligand binding in order to increase accuracy of binding affinity
estimates and prediction of possible binding modes.
The position of the cubic docking grid for the ATP binding site was centered on the original
co-crystallized ligand centroid and from the binding cavity centroid defined by SiteMap for the
proposed allosteric site with a box size of 29 Å for both. A constrained minimization of the receptor
was performed with an RMSD cutoff of 0.18 Å. An initial softened potential Glide docking of the
ligand set was then implemented with the standard precision (SP) mode and a van der Waals
scaling factor of 0.5 was applied to the non-polar atoms of the receptor and ligands. The resulting
top 20 poses of the ligands were used to sample protein plasticity by conformational searches and
minimizations of binding pocket residues within 6 Å of any ligand pose for all complexes obtained.
The new receptor conformations were then redocked using complexes within 30 kcal/mol from the
best scoring structure. Glide docking parameters for this step were reset to the default hard
potential function with a van der Waals scaling of 1.0 and SP mode.
The estimated binding affinity of each complex was reported in the GlideScore and used to
compare differences between each ligand while the Emodel score is used to inter-compare poses
of the ligands. Emodel places more significance on weighting force field components (electrostatic
and van der Waals energies), making it better for comparing conformers as opposed to comparing
chemically-distinct species.
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5.2.3.6.

Quantum polarized ligand docking (QPLD)

To account for ligand polarization upon binding, Quantum Mechanics/Molecular Mechanics
(QM/MM) docking was performed by the Schrödinger QM-Polarized Ligand Docking Protocol
(QPLD) 129–132. The protocol first employs RRD using Glide in SP mode. In this step, the top five
poses of each ligand in the initial RRD were used. Potential ligand polarization induced by the
protein were then calculated with QSite

131,133,134

at the B3LYP/6-31G* level. The ligand force

fields were then reconstructed with QM/MM modified charges, redocked, and five poses of each
ligand were saved for evaluation.

5.2.3.7.

Molecular mechanics and generalized born surface area (MM/GBSA)

The MM/GBSA method combines molecular mechanics energy terms and implicit solvation
models to calculate the binding-free energy based on docking complexes. The protocol,
implemented by the Prime MM-GBSA module, calculates optimized free energies for the free
protein and free ligand and references them with the original bound complex energy

135

. Polar

contributions are calculated using the Generalized Born (GB) model 136, an implicit solvent model
is based on a variable dielectric surface Generalized Born (VD-SGB) approach, where the variable
dielectric value for each residue was fit to a large number of side-chain and loop predictions while
the non-polar energy is estimated using the solvent accessible surface area (SASA)

137

. The

simulation was performed based on receptor–ligand complex structures obtained from induced fit
docking. The obtained ligand poses were minimized using the local optimization feature in Prime,
whereas the energies of complex were calculated with the OPLS-3 force field and GeneralizedBorn/Surface Area continuum solvent model 138. During the simulation process, the ligand strain
73

energy is also considered. A known issue with MM/GBSA is that scores do not accurately
reproduce absolute physical binding affinities but display great efficacy at ranking compounds in
a relative manner

139–142

. We developed a correlation function using a single-layer logistic

regression to rescale MM/GBSA scores based on the other docking score algorithms. This retains
the ranking accuracy of MM/GBSA and allows us to proportion the results in a minimally biased
and physically relevant manner.

5.2.3.8.

Virtual target screening (VTS)

VTS is a system designed to virtually screen a molecule of interest to a large library of protein
structures. The current protein library consists of 1,451 structures with a concentration of kinases.
The system is calibrated with a set of small drug-like molecules are docked against each structure
in the protein library to produce benchmark statistics. VTS was employed as a theoretical assay of
potential kinase activity and gauge of potential biological promiscuity. The calibration procedure
allows the analysis to accurately predict inhibitor–kinase binding affinities when Kd < 10 μM
(defining a hit) and Kd ≥ 10 μM are both considered (72% accuracy in the best case) 143. Therefore,
the VTS system is able to robustly discriminate protein binders from nonbinders and give some
inclination as to potential binding promiscuity of the molecule of interest with respect to the protein
group tested.

5.2.4

Cell culture
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The CCOC cells lines TOV21G and ES-2 were cultured in MCDB 131: Media 199(1:1 ratio)
and McCoy’s medium, respectively, supplemented with 10% FBS, 100 units/ mL of penicillin and
100μg/mL of streptomycin. The immortalized normal human endometrial stromal cell line,
SHT290, was maintained in F12K: Media 199 (1:1 ratio) and supplemented with 5% FBS, 0.1%
Mito +, 2μg/mL of human insulin, 100 units/mL of penicillin and 100μg/mL of streptomycin. All
cell cultures represented were passaged less than 10 times. Cell cultures were maintained in an
incubator at 37 °C and 5% CO2 atmosphere.

5.2.5

Atypical PKC expression during rapid growth and cell cycle arrested

SHT290, TOV21G and ES-2 cells were seeded into 100mm plates and grown to 50%
confluency. Rapidly growing cells were harvested at 50% confluence and the cell cycle arrested
cells were serum starved for an additional 48 hrs in reduced serum medium Opti-MEM I (N=3).

5.2.6

Preliminary screening of TOV21G and ES-2 with ICA-1S and ζ-Stat

TOV21G and ES-2 cells were seeded into 100mm plates and grown to 50% confluency.
Control cells were treated with equal amounts of DMSO (vehicle) and treatment cells were treated
with 3µM concentrations of ICA-1S and ζ-Stat for 24, 48 and 72 hrs (N=3). Cells were collected
at 24, 48 and 72 hrs and run on a Western blot.

5.2.7

Cell viability assay
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Cells were seeded in to 96-well plate at 800 cells per well with 200µL of media. Cells were
treated with different concentrations of DMSO (vehicle to match treatment, N=12) and ζ-Stat
(1μM, 3μM, 5μM and 10µM, N=3). After 72 hrs of treatment, the cell viability was analyzed using
WST-1 at wavelengths 450 and 630 nm. The plates were read on a BioTek SynergyHT microplate
reader. Standard curves for each cell line was generated based on the number of cells added and
the absorbance recorded.

5.2.8

Cell lysate collection

Media was extracted from the vessel and 250μL of lysis buffer [Pierce® Immuno Precipitation
Lysis Buffer, 25 mM Tris-HCl pH 7.4, 150 mM NaCl, 1 mM EDTA, 1% NP-40 and 5% glycerol]
with protease and phosphatase inhibitors was added to the plates. Cells were scraped and collected
from the vessel (on ice) and the suspension was sonicated for 3 x 5 s cycles on ice. The samples
were centrifuged at 4°C at 12,000 x g for 15 ms. The supernatant (cell lysate) was removed from
the cellular membrane pellet and placed in a secondary micro centrifuge tube. Protein content was
measured per Bradford Assay Reagent on a BioTek SynergyHT microplate reader at 595nm.

5.2.9

Western Blot Analysis

Cell lysates containing equal amounts of protein (20-40µg) were loaded in each lane and run
on sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) and transblotted to a
0.45µm nitrocellulose membrane. Cell lysates were probed with the primary antibodies against
PKC-ζ, PKC-ι, RhoA and β-actin (for loading control) and re-probed with secondary antibodies
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for development. Immunoreacted bands were visualized by enhanced chemiluminescence per the
manufacturer’s

instructions

[Thermo

Scientific™

SuperSignal™

West

Pico

PLUS

Chemiluminescent Substrate]. Band densitometry was performed with ImageJ FIJI 144 software
and normalized densities were derived by the ratio of the protein of interest over the control (βactin).

5.2.10 Endpoint PCR
The mRNA from TOV21G and ES-2 cells treated with vehicle control and 3μM of ζ-Stat was
isolated via the manufacture’s protocol for RNAbee. The mRNA was then quantified using the
BioTek Synergy HT Take5 plate and cDNA was synthesized using the Qiagen reverse
transcription (RT) kit per the manufacturer’s protocol. Endpoint polymerase chain reaction (PCR)
was performed with primers for RhoA and the house keeping gene GAPDH (forward 5’CCACCC-ATG-GCA-AAT-TCC-ATG-GCA-3’ and reverse 5’TCT-AGA-CGG-CAG-GTC-AGGTCC-ACC-3’). PCR products were analyzed on an agarose gel (N=3).

5.2.11 Rac1 activation assay
Cells were cultured in 150mm plates and lysed as previously described. The cells were treated
with DMSO (control) and 10µM of ζ-Stat for 72 hrs and harvested (N=4). Glutathione Stransferase (GST) was tagged to the protein binding domain (PBD) of p21 activated kinase (PAK).
A positive control and negative control were performed to determine assay efficiency. Briefly,
500µg of protein were balanced in 200µL of cell lysis for each sample. The positive control
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received 200µM of non-hydrolyzable guanosine 5'-O-[gamma-thio] triphosphate (GTPγS) and the
negative control received 200µM of guanosine diphosphate (GDP). These samples were incubated
at room temperature (RT) for 15 ms. All samples (positive, negative, DMSO control and treatment)
were incubated with GST-tagged PAK-PBD agarose beads for 1hr 4°C. These samples were
pelleted at 5,000 x g (at 4°C) and washed with Wash Buffer. The pelleted beads were re-suspended
with 20µL of 2X Laemmli sample buffer and boiled at 95°C for 2 ms.

5.2.12 Preparation of cytoplasmic and nuclear extracts
TOV21G and ES-2 cells were seeded in 100mm tissue culture plates (1.5x105). Cells were
treated for 72 hours with 10μM ζ-Stat (DMSO control) and harvested with trypsin. The instructions
provided by the manufacturer were followed to fractionate the cytoplasmic and nuclear portions.
The extracts were analyzed via immunoblots and translocation of Ect2 was investigated.

5.2.13 Fluorescent microscopy
TOV21G cells were seeded into 4 chambered slides at a 500 cells per well concentration and
after 24 hrs, were treated with a vehicle control (DMSO) and 10µM of ζ-Stat every 24 hrs for 72
hrs. Cells were then fixed with 4% paraformaldehyde for 15 ms and immunostained with Ect2
antibody at 4°C overnight with light agitation. The slides were incubated with Alexa 488 rabbit
secondary antibody for 1 hr at room temperature RT. Subsequently, the slides were stained with
Phalloidin conjugated to Texas red dye for 30 ms at RT, mounted with solution containing 4′,6-
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diamidino-2-phenylindole (DAPI) and imaged on an Olympus BX53 Digital Upright Fluorescent
Microscope.

5.2.14 Invasion assay
For the evaluation of invasion, cells were serum starved for 48 hrs, followed by detachment
and plating into the upper chamber of a 96-well (8 µm) transwell permeable support, coated with
0.1X BME. Serum (10%) containing media was loaded into the lower chamber as a
chemoattractant. Subsequently, TOV21G cells at the upper chamber were treated with 10μM of ζstat for 24 hr (N=4). Two experimental treatment groups for the cells were performed: Control
(DMSO vehicle) and treatment. The invasive cells that passed into the lower chamber were then
fixed with 4% paraformaldehyde, stained with 2% crystal violet in 2% ethanol, washed with
distilled water and photographs were captured after drying using a light microscope Motic AE31E.
For migration, a similar protocol was followed except without coating the transwell insert with
BME. The assay was quantified with ImageJ FIJI software.

5.2.15 ζ-Stat in-vivo
The following experiments outline the investigations of ζ-Stat in TOV21G clear cell carcinoma
ovarian xenografts. We have an Institutional Animal Care and Use Committee (IACUC) approved
by Adrienne Booker for the discussed studies. The study involved 12 athymic female nude mice
weighing between 20-25g and >10 weeks of age. The 12 mice were divided into two groups after
TOV21G cells were implanted (1 x 106 cells/per mouse flank in 0.2mL of media). The first group
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was the vehicle control group (N=6), which received 100 µL of 1x DPBS. The second group (N=6)
was injected with 100 µL of 20mg/kg of ζ-Stat dissolved in 1x DPBS. The tumor volume was
calculated using the formula: length x width x width x ½. Three days after the implantation of the
cells, tumors were treated as of day 0. The treatments were administered every other day
subcutaneously intra-tumor and around the tumor site for 35 days.
At the end point of the experiment, tumors and heart serum were harvested. Tumors were
imaged and measured, and blood serum was analyzed for enzymatic levels of glucose (GLU),
blood urea nitrogen (BUN), alanine aminotransferase (ALT), aspartate aminotransferase (AST)
and alkaline phosphatase (ALKP) at the Moffitt Research Facility. Briefly, blood chemistry
analysis was performed by initially collecting whole blood in a serum separator tube, which then
sat for 20 ms at RT before centrifugation. Once the blood was centrifuged the serum was separated
and placed in a specialized sample cup made for the IDEXX CatalystDx. The cup containing the
serum and the desired chemistry slides were then placed into the CatalystDx for analysis.

5.2.16 In-vivo tumor fractionation
Tumors were re-suspended and sonicated in 700 μL of homogenization buffer [Pierce®
Immuno Precipitation Lysis Buffer, 25 mM Tris-HCl pH 7.4, 150 mM NaCl, 1 mM EDTA, 1%
NP-40 and 5% glycerol]. The suspension was sonicated for 3 x 5 sec cycles on ice. The tumor
suspensions were centrifuged at 12,000 x g for 15 mins to obtain cell extracts. The supernatant
was removed and protein content was measured using Bradford reagents.
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5.2.17 Statistical analysis
R studio software was used for statistical analyses

145

. A one-way ANOVA with a Tukey’s

multiple comparisons test was performed for Western Blot analyses and cell viability. A two-tailed
unpaired student T-test was utilized for the statistical significance of the particle counts for cell
migration and invasion, day to day tumor volume, mouse body weight and individual enzyme
levels. The Pearson’s Correlation Coefficient (PCC) was utilized for co-localization and was
analyzed using ImageJ FIJI software, using the Coloc2 plugin.
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